{"slug":"bpc-157","verification":{"valid":true,"entries":181,"head":"10774e844a8162e603a29c0df2a0da53d46ae99da423a941da68e1cb161e0181"},"energy":{"passes":181,"tokens_in":519336,"tokens_out":24429,"tokens_total":543765,"cost_usd":0,"models":{"grok/grok-4.3":72,"grok-4.3":21,"ingest:deterministic":54,"repair":10,"fill-slots":5,"kimi/moonshot-v1-8k":3,"gemini/gemini-2.5-flash":1,"system/repair":5,"conversation-router":2,"system/audit-repair":5,"owner":1,"user":2},"head":"10774e844a8162e603a29c0df2a0da53d46ae99da423a941da68e1cb161e0181"},"provenance":[{"ts":"2026-06-29T08:26:03.704Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: BPC-157: Body Protection Compound\n\nGeneral evidence-graded intro for BPC-157: Body Protection Compound. Data-first peptide definition article.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"bpc-157-body-protection-compound\",\n  \"title\": \"BPC-157: Body Protection Compound\",\n  \"body\": \"## Overview\\nBPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein sequence. It has been investigated primarily in preclinical models for local tissue responses involving angiogenesis and repair processes.\\n\\n## Preclinical Evidence\\nOver 100 animal and cell studies have examined BPC-157 in models of tendon, gut, muscle, bone, and nerve injury. These consistently report accelerated healing parameters such as improved collagen organization and vascular ingrowth at injury sites (preclinical tier).\\n\\n## Human Data\\nA 2025 pilot study reported intravenous infusion of up to 20 mg BPC-157 in two healthy adults produced no adverse effects on vital signs, blood biomarkers, or subjective reports (human tier). Limited retrospective reports describe intra-articular use in small patient groups for knee pain, though these lack controls.\\n\\nNo large-scale randomized controlled human trials for efficacy in tissue repair are documented. Earlier mentions of clinical testing for inflammatory bowel disease refer to older development programs that did not lead to regulatory approval.\\n\\n## Mechanisms\\nProposed actions include promotion of local angiogenesis and interaction with nitric oxide pathways in damaged tissue (mechanistic tier). These derive from rodent and in-vitro observations.\\n\\n## Limitations\\nEvidence separating rat studies from human trials remains sparse for functional outcomes. User reports exist on anecdotal platforms but are not graded here as they fall outside controlled data tiers.\",\n  \"register\": \"source_ledger\",\n  \"claims\": [\n    {\n      \"id\": \"c1\",\n      \"text\": \"BPC-157 is a synthetic 15-amino-acid peptide derived from a gastric juice protein sequence.\",\n      \"section\": \"Overview\",\n      \"tier\": \"mechanistic\",\n      \"source_ids\": [\"s1\"],\n      \"source_status\": \"sourced\",\n      \"why_material\": \"Establishes identity and origin f","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"0760a17ff56e7b5314b189444fe2ee858de967fdb074f6246dc0689e88877b4c"},{"ts":"2026-06-29T08:34:55.668Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0760a17ff56e7b5314b189444fe2ee858de967fdb074f6246dc0689e88877b4c","hash":"b4353a9869bbd0bb9f9206ff73a6f928d5da6939b26739b2c3c9febde01e4e80"},{"ts":"2026-06-29T08:35:14.703Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b4353a9869bbd0bb9f9206ff73a6f928d5da6939b26739b2c3c9febde01e4e80","hash":"ce9ffb17d696526f7c0e1ca0b2e1b0a9db9b611c067bab87a3c5d69674b69646"},{"ts":"2026-06-29T09:23:26.489Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ce9ffb17d696526f7c0e1ca0b2e1b0a9db9b611c067bab87a3c5d69674b69646","hash":"eb30f25be75c3a14e9ba4bc5820af53e62d605957e121b0212064c60f04658cd"},{"ts":"2026-06-29T09:23:53.759Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"eb30f25be75c3a14e9ba4bc5820af53e62d605957e121b0212064c60f04658cd","hash":"8ab1aa1b8c94eab236d0735beb2ff49258475bf1169abab498857dc8ae058447"},{"ts":"2026-06-29T09:24:26.430Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8ab1aa1b8c94eab236d0735beb2ff49258475bf1169abab498857dc8ae058447","hash":"21a150d6d147bf5c9322b955441e986cd519f3ca7228126c55eada58e1b07e36"},{"ts":"2026-06-29T09:24:28.990Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"21a150d6d147bf5c9322b955441e986cd519f3ca7228126c55eada58e1b07e36","hash":"5d2e4cd2691ccca0f978e80a2041aed5ff97103896e13609ff5df5f574486ac9"},{"ts":"2026-06-29T09:25:23.882Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5d2e4cd2691ccca0f978e80a2041aed5ff97103896e13609ff5df5f574486ac9","hash":"5710b7eb871dc527ec49d80c8a5e998ecfe9ecea4d05759761d84a3a2bd37e0a"},{"ts":"2026-06-29T09:25:26.230Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5710b7eb871dc527ec49d80c8a5e998ecfe9ecea4d05759761d84a3a2bd37e0a","hash":"4d0920d908fe7a06fdd6944db8c89d9e6d370ba85306cd167bbdeb143ebf74dc"},{"ts":"2026-06-29T09:27:59.126Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4d0920d908fe7a06fdd6944db8c89d9e6d370ba85306cd167bbdeb143ebf74dc","hash":"675e60891b817d269396c58e86f408bc0e2924f2bb3ad50412a182ce19c26981"},{"ts":"2026-06-29T09:28:01.288Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"675e60891b817d269396c58e86f408bc0e2924f2bb3ad50412a182ce19c26981","hash":"39eee33bd77d837c2037405e60c5d90e52f5d892866082c8fd1d2634d9d8ae40"},{"ts":"2026-06-29T09:35:09.466Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"39eee33bd77d837c2037405e60c5d90e52f5d892866082c8fd1d2634d9d8ae40","hash":"d20fb3ffff76ceb6249073ed3ecb89c2d0fe774208a1794dae18087ae288c0e3"},{"ts":"2026-06-29T09:35:30.963Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d20fb3ffff76ceb6249073ed3ecb89c2d0fe774208a1794dae18087ae288c0e3","hash":"4b119940d3e4560d6107934724be620e78d57b630cd116a15e7044de2a461045"},{"ts":"2026-06-29T09:35:53.301Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4b119940d3e4560d6107934724be620e78d57b630cd116a15e7044de2a461045","hash":"de1d1bb38f4a579513222011a78f4f11b2798f85066e8b36b0f9b980ae1c8686"},{"ts":"2026-06-29T09:36:13.720Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"de1d1bb38f4a579513222011a78f4f11b2798f85066e8b36b0f9b980ae1c8686","hash":"e711a9db9d84130b827f6b3d105c9029b40a5677c67770af57f507e21a89ec96"},{"ts":"2026-06-29T09:37:07.317Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e711a9db9d84130b827f6b3d105c9029b40a5677c67770af57f507e21a89ec96","hash":"e954c62f3018008452e3d8ed79946c169b829fa48970714715a16faf95e96714"},{"ts":"2026-06-29T09:37:29.043Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"7 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e954c62f3018008452e3d8ed79946c169b829fa48970714715a16faf95e96714","hash":"9abe46919467cd5c5defce4c211d63a3cd3d3076d0854e2a40daae7a10dc665f"},{"ts":"2026-06-29T09:37:44.822Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9abe46919467cd5c5defce4c211d63a3cd3d3076d0854e2a40daae7a10dc665f","hash":"8bda058a2f15a32cef2e29f31d7bd3fc6c3e962acbd5ede2f3561d59bf0a6f68"},{"ts":"2026-06-29T10:20:41.131Z","model":"repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":51,\"before\":[\"10 claims missing posted_by\",\"51 orphan sources (no claim link)\",\"missing constitution slots: who_claims_what, what_is_known, what_is_unknown, limitations, disclaimer\"],\"after\":[\"missing constitution slots: what_is_known, what_is_unknown, limitations, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8bda058a2f15a32cef2e29f31d7bd3fc6c3e962acbd5ede2f3561d59bf0a6f68","hash":"f01b7a8e5628aab64729cb7b7882d4a588667d08658254b9e82e923f38b67c72"},{"ts":"2026-06-29T10:29:28.380Z","model":"fill-slots","action":"claim","prompt":"","input":"bpc-157 c62","response":"Per this ledger on BPC-157: Body Protection Compound: 29 scientific and 26 anecdotal sources are catalogued; 1 human-tier claim(s) cite controlled or pilot data (e.g. s3). 28 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f01b7a8e5628aab64729cb7b7882d4a588667d08658254b9e82e923f38b67c72","hash":"e2f1f8c8ff4ff621ac1af77021783eb41310dd53d2048f86de3ef77712b05a21"},{"ts":"2026-06-29T10:29:28.435Z","model":"fill-slots","action":"claim","prompt":"","input":"bpc-157 c63","response":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e2f1f8c8ff4ff621ac1af77021783eb41310dd53d2048f86de3ef77712b05a21","hash":"bf9ec781b036921263b8674739a57abecc4ad40b9a9d2827548becb89ff2d989"},{"ts":"2026-06-29T10:29:28.505Z","model":"fill-slots","action":"claim","prompt":"","input":"bpc-157 c64","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"bf9ec781b036921263b8674739a57abecc4ad40b9a9d2827548becb89ff2d989","hash":"ebfd3eb50f132acafecb7aba152fd80eb0631a4a619d5e4423173561c483ac0c"},{"ts":"2026-06-29T10:29:28.608Z","model":"fill-slots","action":"claim","prompt":"","input":"bpc-157 c65","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ebfd3eb50f132acafecb7aba152fd80eb0631a4a619d5e4423173561c483ac0c","hash":"2ddbdca6063b4048471d673ba3837d780920ba2b5cc4e6cb2fd2cf53dd5a9a03"},{"ts":"2026-06-29T10:56:18.560Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"bpc-157","response":"I added explicit gaps regarding what is unknown and named who claims what from anecdotes where missing, as per the instructions.","tokens_in":2751,"tokens_out":368,"cost":0,"prev":"2ddbdca6063b4048471d673ba3837d780920ba2b5cc4e6cb2fd2cf53dd5a9a03","hash":"d2863c90805cefe0948ab4702cdc4662c56f2bcdfb2b94c81dacd2bdbfcaf62f"},{"ts":"2026-06-29T11:00:59.811Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"bpc-157","response":"I am adding explicit gaps regarding what is unknown and identifying who claims what from anecdotes that are missing in the provided topology.","tokens_in":2757,"tokens_out":348,"cost":0,"prev":"d2863c90805cefe0948ab4702cdc4662c56f2bcdfb2b94c81dacd2bdbfcaf62f","hash":"fd9a7778b1d6f77d149caab6a746a60c41cb8b077501b9c7458f0cd20b425075"},{"ts":"2026-06-29T11:04:12.350Z","model":"gemini/gemini-2.5-flash","action":"collaborate","prompt":"","input":"bpc-157","response":"I am Gemini, not Grok. I added two claims to address gaps in the ledger regarding the known limitations of human data and to incorporate a public discussion source. The first claim highlights the significant unknown regarding long-term human safety and efficacy, which is crucial for a complete understanding of BPC-157. The second claim captures a public-facing discussion about the compound's efficacy, reflecting broader interest and critical evaluation.","tokens_in":2466,"tokens_out":363,"cost":0,"prev":"fd9a7778b1d6f77d149caab6a746a60c41cb8b077501b9c7458f0cd20b425075","hash":"9cd17d153811e243a1a1a09ca3d158a2cf05f9f88e231c6b199b10a9184eb6c3"},{"ts":"2026-06-29T11:11:28.937Z","model":"repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9cd17d153811e243a1a1a09ca3d158a2cf05f9f88e231c6b199b10a9184eb6c3","hash":"aef5d6ba8b0fad0b8c07e18080bfbdb5d48fd45eb9d586acd7dc9553b151960e"},{"ts":"2026-06-29T11:12:25.292Z","model":"system/repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"aef5d6ba8b0fad0b8c07e18080bfbdb5d48fd45eb9d586acd7dc9553b151960e","hash":"489467820a3bd6a33649f2da2457f18be0ae10027ff18b5b7e19962827858a12"},{"ts":"2026-06-29T11:12:25.822Z","model":"system/repair","action":"retract","prompt":"","input":"bpc-157 c7","response":"Duplicate — merged into c5 by ledger harden","tokens_in":0,"tokens_out":0,"cost":0,"prev":"489467820a3bd6a33649f2da2457f18be0ae10027ff18b5b7e19962827858a12","hash":"6816d3b1122e96eb9d278008f4470b81fa9fa4fdd039ea8a9d0be60f3fc14974"},{"ts":"2026-06-29T11:12:26.056Z","model":"system/repair","action":"retract","prompt":"","input":"bpc-157 c8","response":"Duplicate — merged into c6 by ledger harden","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6816d3b1122e96eb9d278008f4470b81fa9fa4fdd039ea8a9d0be60f3fc14974","hash":"5ea9574f657846ba70aec8bae73315e13b26c061d90e8b017ec25c969fae2abd"},{"ts":"2026-06-29T11:12:26.402Z","model":"system/repair","action":"retract","prompt":"","input":"bpc-157 c9","response":"Duplicate — merged into c5 by ledger harden","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5ea9574f657846ba70aec8bae73315e13b26c061d90e8b017ec25c969fae2abd","hash":"ffaa2392cbb867a390072beae6dcb41d784746d1a5fa28fbe81fee6f27ce02d2"},{"ts":"2026-06-29T11:12:26.641Z","model":"system/repair","action":"retract","prompt":"","input":"bpc-157 c10","response":"Duplicate — merged into c6 by ledger harden","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ffaa2392cbb867a390072beae6dcb41d784746d1a5fa28fbe81fee6f27ce02d2","hash":"75eedad2010abf67808f58a2210ca7f9e8c6f28db9b907a882601696c6c8245e"},{"ts":"2026-06-29T11:12:26.888Z","model":"repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"75eedad2010abf67808f58a2210ca7f9e8c6f28db9b907a882601696c6c8245e","hash":"e18e8325b8a13bb9d85721f98987fd5b8b4e174a25f58f9c2ffb5617616200ef"},{"ts":"2026-06-29T12:20:05.382Z","model":"kimi/moonshot-v1-8k","action":"claim","prompt":"","input":"bpc-157 c72","response":"The source monoculture is a real problem but the constitution is the bootstrap source so it is acceptable.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e18e8325b8a13bb9d85721f98987fd5b8b4e174a25f58f9c2ffb5617616200ef","hash":"6b1a049144dc06482c1de0bd612b2f9d217b7681ee3d0d21f3110008d1fae3d7"},{"ts":"2026-06-29T12:20:05.956Z","model":"conversation-router","action":"claim","prompt":"","input":"bpc-157 c73","response":"Source monoculture weakens epistemic diversity because 41 active claims cite the same bootstrap source s1.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6b1a049144dc06482c1de0bd612b2f9d217b7681ee3d0d21f3110008d1fae3d7","hash":"1ada5bb184054ba87e4592c5ca6a3056a3a17adc58574dfbfb54225b656dc4f5"},{"ts":"2026-06-29T12:20:22.590Z","model":"conversation-router","action":"claim","prompt":"","input":"bpc-157 c74","response":"The source monoculture is a real problem but the constitution is the bootstrap source so it is acceptable.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1ada5bb184054ba87e4592c5ca6a3056a3a17adc58574dfbfb54225b656dc4f5","hash":"6e54805e54d13e91e3d3f8e386e61ef6c61d48b5455483ab9ff8481f9bd2f012"},{"ts":"2026-06-29T12:29:42.452Z","model":"repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6e54805e54d13e91e3d3f8e386e61ef6c61d48b5455483ab9ff8481f9bd2f012","hash":"b6a197a2eadee83f38e11d5f01297902288f862ba976bda3f02163a7e0dc856e"},{"ts":"2026-06-29T12:45:23.092Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b6a197a2eadee83f38e11d5f01297902288f862ba976bda3f02163a7e0dc856e","hash":"193ce33362d9577bb467d79acb73ced24f4e7a556a8fc1ba10210bc2fb7a517d"},{"ts":"2026-06-29T13:26:08.790Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"193ce33362d9577bb467d79acb73ced24f4e7a556a8fc1ba10210bc2fb7a517d","hash":"ed46626d57d6c623a5258187472b1cf90a958ec77fe7b0faea9dc473da36b47f"},{"ts":"2026-06-29T13:26:09.987Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ed46626d57d6c623a5258187472b1cf90a958ec77fe7b0faea9dc473da36b47f","hash":"314a6bb78a0f15b6a8ae602eaf26fba9cdd1d7ef5fc67d6179a47388b8ab15e4"},{"ts":"2026-06-29T13:48:09.453Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: BPC-157: Body Protection Compound\n\nRules: separate human trials from rat studies from Reddit/X anecdotes. Label every claim tier. Repair-vs-suppression framing where relevant. No medical claims. register: source_ledger.","response":"{\n  \"slug\": \"bpc-157-body-protection-compound-evidence-review\",\n  \"title\": \"BPC-157: Body Protection Compound – Evidence Ledger\",\n  \"body\": \"## Overview\\nBPC-157 (Body Protection Compound-157) is a synthetic gastric pentadecapeptide. All statements below are graded by evidence tier with sources.\\n\\n## Human Data\\nNo large randomized controlled trials with published efficacy results exist. One Phase 2 trial is recruiting (NCT07437547) for acute hamstring strain repair using MRI endpoints and return-to-sport time; estimated completion 2028; status recruiting as of Feb 2026. Three small pilot or retrospective reports describe intra-articular knee injections (n=16, subjective pain recall at 6-12 months), bladder-wall injections for interstitial cystitis (n=12 women, single session), and intravenous dosing in two healthy adults (safety/tolerability only). No human data on long-term outcomes or repair mechanisms.\\n\\n## Preclinical (Rat) Studies\\nMultiple rat models show accelerated tendon transection healing, tendon-to-bone reattachment, myotendinous junction repair, and spinal cord injury recovery with functional, biomechanical, and histological improvements versus controls. Effects observed across intraperitoneal, oral, and topical routes; mechanisms include angiogenesis, collagen organization, and counteraction of corticosteroid impairment.\\n\\n## Anecdotal Reports\\nUser reports on forums describe perceived reductions in joint/tendon pain and faster perceived recovery after self-administered courses, often alongside rest or rehab. Reports vary in dose, route, and outcome; placebo, concurrent interventions, and reporting bias unquantified.\\n\\n## Framing Notes\\nPreclinical findings emphasize tissue-level repair processes rather than symptom suppression alone. Human data insufficient to distinguish repair from other effects.\",\n  \"register\": \"standard\",\n  \"claims\": [\n    {\n      \"id\": \"c1\",\n      \"text\": \"No large published RCTs demonstrate BPC-157 efficacy or long-term saf","tokens_in":0,"tokens_out":0,"cost":0,"prev":"314a6bb78a0f15b6a8ae602eaf26fba9cdd1d7ef5fc67d6179a47388b8ab15e4","hash":"f7ed89d1cb4cc5a604df2b435ef41b4986313ec335db3b47dd66e2eec92c1ece"},{"ts":"2026-06-29T13:49:20.472Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f7ed89d1cb4cc5a604df2b435ef41b4986313ec335db3b47dd66e2eec92c1ece","hash":"fc494c7b8a672b40ac600c78317433ac9af686d0b01a958b247253885a140a95"},{"ts":"2026-06-29T13:49:37.450Z","model":"repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fc494c7b8a672b40ac600c78317433ac9af686d0b01a958b247253885a140a95","hash":"8f6cd1bf2f32ddd0cb1deee32846a4726e0c2aff94153999530d9e676f5badb8"},{"ts":"2026-06-29T13:49:52.089Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8f6cd1bf2f32ddd0cb1deee32846a4726e0c2aff94153999530d9e676f5badb8","hash":"757498286a731af386df31a1ed73564f367d7caf5237590ab95ba337c54d2908"},{"ts":"2026-06-29T13:50:13.704Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"2 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"757498286a731af386df31a1ed73564f367d7caf5237590ab95ba337c54d2908","hash":"d50b52d0f66531567db044711c8b5b176d2b00b6edb53e98f4f7b54b4a4a8d8a"},{"ts":"2026-06-29T13:50:34.052Z","model":"repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d50b52d0f66531567db044711c8b5b176d2b00b6edb53e98f4f7b54b4a4a8d8a","hash":"3e9a209ee0f4bcf3efb18bea932362f401ed67ae003138ed2cbd8b22414e8697"},{"ts":"2026-06-29T13:53:45.780Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"3e9a209ee0f4bcf3efb18bea932362f401ed67ae003138ed2cbd8b22414e8697","hash":"58c628422d534d9da4a8dd397511203afbe460416e55da92bc2db8129d4919a4"},{"ts":"2026-06-29T13:53:46.940Z","model":"system/audit-repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"58c628422d534d9da4a8dd397511203afbe460416e55da92bc2db8129d4919a4","hash":"9af1fed65c5084e702bc378fc5c8da1136d673db2e6d1e6235648e6a37ae8f1a"},{"ts":"2026-06-29T14:15:54.059Z","model":"grok/grok-4.3","action":"synthesize_body","prompt":"","input":"bpc-157","response":"## Regeneration vs degeneration — where this fits\n\nThe body breaks down tissue and builds it back at the same time. When breakdown stays ahead of repair, pain or weakness stays. Most drugs lower the pain or swelling signal without changing the damaged tissue. BPC-157 is studied for a different path: it is examined for steps that bring new blood vessels to an injury site so repair cells and materials can reach the area. That path is regeneration, not signal suppression.\n\n## What it is\n\nBPC-157 is a short chain of 15 amino acids first taken from human stomach fluid. It is stable in stomach acid. The compound is examined for effects on blood vessel growth, collagen building, and cell movement at injury sites. All studies in the ledger come from one research group in Croatia.\n\n## How it works\n\nThe proposed steps are:\n1. BPC-157 reaches the injury site.\n2. It raises signals for new blood vessel formation (angiogenesis).\n3. It increases collagen production and fibroblast activity.\n4. It changes nitric oxide balance in ways that support vessel function.\n5. These changes are studied in tendon, muscle, ligament, and gut lining models.\n\n## Why it would work (logic chain)\n\nIf new blood vessels form at a damaged site, more oxygen and repair cells arrive. If collagen production rises, the tissue matrix can rebuild. If inflammation drops while vessels grow, the repair window stays open longer. Each step follows from the one before. The chain is tested only in animal models so far.\n\n## Why people take it\n\nPeople take it for tendon pain, muscle tears, ligament injuries, and gut issues. The reported goal is faster return to training or daily activity. Some use it after surgery. Some use it for chronic tendon problems that have not resolved with rest or physical therapy.\n\n## How many people take it\n\nNo reliable count exists. The ledger records 21 Reddit posts and 1 X post that mention personal use. Three small human safety or case reports are listed. Population numbers cannot be calc","tokens_in":7810,"tokens_out":924,"cost":0,"prev":"9af1fed65c5084e702bc378fc5c8da1136d673db2e6d1e6235648e6a37ae8f1a","hash":"02e49189920116208bbea2b6b8f33414fdd4b8ac6ad6ea157ae90c7c736214a9"},{"ts":"2026-06-29T15:06:30.568Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"02e49189920116208bbea2b6b8f33414fdd4b8ac6ad6ea157ae90c7c736214a9","hash":"52ba5cd435f1bfcbf30a27e3dfc011bc5c78f0f685186b05d2058cf528f607a6"},{"ts":"2026-06-29T15:07:04.710Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"52ba5cd435f1bfcbf30a27e3dfc011bc5c78f0f685186b05d2058cf528f607a6","hash":"228ed60b9e9d2d6f698dfcd6846b0ffbd2c01f7a1d72b23ecb7dbda1ce011e92"},{"ts":"2026-06-29T15:07:31.054Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"228ed60b9e9d2d6f698dfcd6846b0ffbd2c01f7a1d72b23ecb7dbda1ce011e92","hash":"9807c80fc64c482b9ec6a2a7d1cdcda2e14953db8b3892b2205f24bd9718f102"},{"ts":"2026-06-29T15:08:34.208Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9807c80fc64c482b9ec6a2a7d1cdcda2e14953db8b3892b2205f24bd9718f102","hash":"a8469fd347cadd19adda44c1198a0f46f9ee581e4e3be90335e9853b6d6160f1"},{"ts":"2026-06-29T16:35:05.618Z","model":"repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a8469fd347cadd19adda44c1198a0f46f9ee581e4e3be90335e9853b6d6160f1","hash":"92f18846c7b63e33a4cf46ed5ea8dcc8088841efc02bf7f783c4f91af95e84fd"},{"ts":"2026-06-29T16:59:51.881Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"92f18846c7b63e33a4cf46ed5ea8dcc8088841efc02bf7f783c4f91af95e84fd","hash":"1f85e038f2d21869bc2a42dd494e810161d649d682239d277b5c0c6d191b7e16"},{"ts":"2026-06-29T17:00:42.046Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"6 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1f85e038f2d21869bc2a42dd494e810161d649d682239d277b5c0c6d191b7e16","hash":"3eb3e354f783a137716cd39e61b97751933a8883c94aa8bb59255a58bd0f0cec"},{"ts":"2026-06-29T17:01:25.653Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"3eb3e354f783a137716cd39e61b97751933a8883c94aa8bb59255a58bd0f0cec","hash":"97fa6051b18ca98b3d659621219e39ef1fe4eb4341943816fd8f81340768659f"},{"ts":"2026-06-29T17:01:57.166Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"3 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"97fa6051b18ca98b3d659621219e39ef1fe4eb4341943816fd8f81340768659f","hash":"8f058d3a49e8176202be80019f0a1541fd04283d41dcbb0947574f69514666d1"},{"ts":"2026-06-29T17:21:22.039Z","model":"grok-4.3","action":"sources","prompt":"","input":"bpc-157","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8f058d3a49e8176202be80019f0a1541fd04283d41dcbb0947574f69514666d1","hash":"a2219ac36771fa2ed4129eb371f0eed834a770ee8edd91df7f3121f08ea026a6"},{"ts":"2026-06-29T19:04:02.794Z","model":"repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: limitations\"],\"after\":[\"missing constitution slots: limitations\"],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":9}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a2219ac36771fa2ed4129eb371f0eed834a770ee8edd91df7f3121f08ea026a6","hash":"da441ec407f5dbc7b97481391ac150ceea101be15ba9a24b03d4058d21c481f5"},{"ts":"2026-06-29T19:15:03.632Z","model":"repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: limitations\"],\"after\":[\"missing constitution slots: limitations\"],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":9}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"da441ec407f5dbc7b97481391ac150ceea101be15ba9a24b03d4058d21c481f5","hash":"52dfd2d801544b794b8dcc2c1e3bdcb8d6d7b1b1a095746b80dfd0ba9099b7b5"},{"ts":"2026-06-29T20:20:04.723Z","model":"fill-slots","action":"claim","prompt":"","input":"bpc-157 c120","response":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"52dfd2d801544b794b8dcc2c1e3bdcb8d6d7b1b1a095746b80dfd0ba9099b7b5","hash":"0962ce35b56aa46301ffc63eaeb72bf1161016b87dfef4126cb1685da3ae9c4d"},{"ts":"2026-06-29T22:00:37.417Z","model":"repair","action":"repair","prompt":"","input":"bpc-157","response":"{\"materialized\":0,\"before\":[],\"after\":[],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":0,\"adjacent\":9}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0962ce35b56aa46301ffc63eaeb72bf1161016b87dfef4126cb1685da3ae9c4d","hash":"d452fcae6d4f2f1da4db2e3d7f671cc311bf6910da7dc9955ab391d401b9ca0c"},{"ts":"2026-07-01T11:28:56.329Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers BPC-157 (preclinical tendon/muscle models + one L4-L5 herniation anecdote), TB-500 (anecdotal stack mentions), and recovery-stack-herniated-disc / bpc-ara-herniated-disc / ara-290-herniated-disc articles (structural mentions only). No dedicated herniated-disc stack with dosing or protocols exists. Evidence is sparse: 1 human safety pilot (c3), rat studies, and anecdotes (c5, c35, c111). Interaction_risk/limitations claims (c120, c67) rank first: long-term human safety unknown, no established dosing/route, source monoculture noted.","tokens_in":7222,"tokens_out":339,"cost":0,"prev":"d452fcae6d4f2f1da4db2e3d7f671cc311bf6910da7dc9955ab391d401b9ca0c","hash":"d60cdad453852b3c274fbd8680ea4966d1072f84b7ebc9d304faecfbbec1cdb5"},{"ts":"2026-07-01T11:29:01.418Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d60cdad453852b3c274fbd8680ea4966d1072f84b7ebc9d304faecfbbec1cdb5","hash":"8f3c14e9dfbe21fc1eb97568fe4ba0913551600383cb287b3582da6b92f9b401"},{"ts":"2026-07-01T11:29:10.234Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"Catalogue contains 30 anecdotal claims total. For herniated discs specifically it records one Reddit anecdote (global_id recovery-stack-herniated-disc or bpc-157:c5) of reduced radicular pain after 8 weeks BPC-157 plus PT (n=1, no imaging). It also records one negative anecdote (c6) of nausea leading to discontinuation. No other disc-specific anecdotes are present; remaining anecdotes cover tendon, knee, elbow, gut, or general tissue use. All anecdotes are tier \"anecdotal\" weight 0.3 or lower; no interaction_risk or limitations-slot claims reference disc use.","tokens_in":7218,"tokens_out":254,"cost":0,"prev":"8f3c14e9dfbe21fc1eb97568fe4ba0913551600383cb287b3582da6b92f9b401","hash":"570650b8e921be21ddeb83df81a085ba6920861b1c3476f19c3aa187288c5f2b"},{"ts":"2026-07-01T11:29:29.529Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Good experiences logged: anecdotal reports of reduced elbow tendinopathy pain with return to climbing (s14/c21), reduced radicular back pain after 8 weeks with PT (s15/c5), improved chronic knee pain allowing return to high-impact activity after 12 weeks combined with TB-500 (s30/c35), faster subjective tendon healing in A2 pulley tear (s31/c36), and reduced inflammation/gut lining support in anecdotal stack use (s83/c101). Bad experiences logged: one user reported nausea within two weeks and discontinued (s16/c6); another reported severe adverse effects (dizziness, migraine, stomach issues, worsened symptoms) after low-dose BPC-157 + TB-500, with partial recovery but lingering effects (s29/c34); additional reports of unusual persistent issues after stopping oral use for shoulder/neck pain (s34/c39). All human data remain limited to small pilots or anecdotes; long-term safety unknown (c67).","tokens_in":7201,"tokens_out":339,"cost":0,"prev":"570650b8e921be21ddeb83df81a085ba6920861b1c3476f19c3aa187288c5f2b","hash":"c4e5f8d6d5d0a3aa5b152422d70c08697d5333f5af60ebe2ae6f8b883a005154"},{"ts":"2026-07-01T11:29:34.567Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c4e5f8d6d5d0a3aa5b152422d70c08697d5333f5af60ebe2ae6f8b883a005154","hash":"1ba2a84415e87b9aa3631a78564e00dbfaae7d0e447ca86b9b895a11a3892a07"},{"ts":"2026-07-01T23:11:16.155Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers: BPC-157 (bpc-157) with one anecdotal claim for L4-L5 herniated disc radicular pain reduction after 8 weeks + PT (global_id bpc-157:c5); BPC-157 + TB-500 combination anecdotes for systemic tissue/tendon healing (bpc-157:c111) and chronic knee pain improvement allowing return to activity (bpc-157:c35); recovery-stack-herniated-disc and bpc-ara-herniated-disc slugs exist but contain no populated claims in the provided topology. Safety-first limitations slot (bpc-157:c120) states evidence is predominantly preclinical/anecdotal with sparse human data and no dosing or treatment recommendations. Gaps: no human trials specific to herniated discs; no interaction_risk data; no ARA-290 claims populated despite dedicated slugs; no TB-500 standalone herniated-disc claims.","tokens_in":7232,"tokens_out":376,"cost":0,"prev":"1ba2a84415e87b9aa3631a78564e00dbfaae7d0e447ca86b9b895a11a3892a07","hash":"5e9301e5179fd6890b1cb27f37351b091d13d99b215be1aada695e98dfdfceae"},{"ts":"2026-07-01T23:11:21.657Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5e9301e5179fd6890b1cb27f37351b091d13d99b215be1aada695e98dfdfceae","hash":"a5b186ed1c4c2d2cfd39ac24b799a5431c12ff1631bc58b0ad503f9ba2f055a9"},{"ts":"2026-07-01T23:11:31.101Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"The catalogue lists a small number of anecdotal reports tied to herniated discs or back pain. One report (global_id bpc-157:c5) describes reduced radicular pain after 8 weeks of BPC-157 plus physical therapy in a person with L4-L5 herniation (anecdotal, n=1, tier:anecdotal). Several other Reddit self-test posts mention reduced back or knee pain after ~8 weeks but lack imaging follow-up (anecdotal tier). Negative anecdotes exist, including one report of nausea leading to discontinuation (bpc-157:c6 / c122). All such claims are pre-ranked low-weight; interaction_risk and limitations claims (c120) are placed first per the safety-first rule. No controlled human data on herniated discs appear in the topology.","tokens_in":7228,"tokens_out":274,"cost":0,"prev":"a5b186ed1c4c2d2cfd39ac24b799a5431c12ff1631bc58b0ad503f9ba2f055a9","hash":"79f72fd937f156bed6c76af4397c7cd032fd1e2dbb7e34c4d5c81f68b944d5cb"},{"ts":"2026-07-01T23:11:51.576Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Good experiences logged for BPC-157 (tier: anecdotal) include one user with elbow tendinopathy reporting return to climbing after 8 weeks with the elbow described as “almost 100 percent healed” (c21). Other anecdotal reports note reduced back or knee pain after 8 weeks (c22), reduced radicular pain from L4-L5 herniation after 8 weeks with PT (c5), gut lining healing as part of a stack (c101), and significant improvement in chronic knee pain after 12 weeks allowing return to high-impact activity (c35). One climber reported subjectively faster tendon healing from an A2 pulley tear (c36). One combined BPC-157/TB-500 report described systemic tissue and tendon healing (c111).\n\nBad experiences logged (tier: anecdotal) include one user reporting nausea within two weeks leading to discontinuation (c6, c122). One user with TBI history reported severe adverse effects from BPC-157 + TB500 including dizziness, migraine, stomach issues, and worsened symptoms after low-dose injection, with partial recovery but lingering effects (c34). Several Reddit posts note caution regarding use for ACL/knee issues (c27).\n\nScientific evidence tier: one 2-person pilot reported no adverse effects from up to 20 mg IV (c3); human data remain limited to small uncontrolled reports (c24, c67). Long-term safety unknown (c67). Preclinical animal models show consistent tendon/muscle healing signals but cannot be directly applied to humans (c30, c66).\n\nSafety-first claims: long-term human safety and side-effect p","tokens_in":7205,"tokens_out":525,"cost":0,"prev":"79f72fd937f156bed6c76af4397c7cd032fd1e2dbb7e34c4d5c81f68b944d5cb","hash":"3b2a37abfcc5a05d648c64a932e291e04d52e41dde66605ae677489a88c34986"},{"ts":"2026-07-01T23:11:56.910Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"3b2a37abfcc5a05d648c64a932e291e04d52e41dde66605ae677489a88c34986","hash":"bb139cd8fc9a358eee24505d57b47f328c56306e9ab2846a46901dde5848ae66"},{"ts":"2026-07-01T23:54:38.800Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers: BPC-157 (preclinical tendon/muscle healing via angiogenesis, one L4-L5 herniation anecdote with PT), TB-500 (anecdotal combined use with BPC-157 for systemic/tendon healing), recovery-stack-herniated-disc and bpc-ara-herniated-disc (stack context for disc issues). No direct human data or controlled trials on herniated discs. Gaps: no interaction_risk or limitations-slot claims found for disc patients; unknown safety with nerve compression, steroids, or NSAIDs; long-term human safety unknown; no dosing or protocol data.","tokens_in":7245,"tokens_out":278,"cost":0,"prev":"bb139cd8fc9a358eee24505d57b47f328c56306e9ab2846a46901dde5848ae66","hash":"36ad0b18256c0077d2d58af488382479480581d9b5833e7dc19b9fe0b6f30316"},{"ts":"2026-07-01T23:54:44.931Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"36ad0b18256c0077d2d58af488382479480581d9b5833e7dc19b9fe0b6f30316","hash":"b7d540d8d360af6cc73d634ff533b07949846585841b5cd810e8a4adb1c96533"},{"ts":"2026-07-01T23:54:54.302Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"The catalogue lists a small number of anecdotal reports tied to herniated discs or back pain. One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 plus physical therapy (global_id bpc-157:c5). Several other self-test posts mention reduced back or knee pain after eight weeks but without imaging follow-up. These sit in the anecdotal tier (weight ~0.3) and are separate from the preclinical animal studies and the very limited human data. No controlled human evidence for disc herniation appears in the topology. Limitations-slot claims (bpc-157:c120, c67) are placed first: human data remain sparse, long-term safety unknown, and no dosing or treatment advice is given.","tokens_in":7241,"tokens_out":267,"cost":0,"prev":"b7d540d8d360af6cc73d634ff533b07949846585841b5cd810e8a4adb1c96533","hash":"e680ebc529f262bf068ae60edb4e0cde68eb4b20871641942586b2bf53ccb572"},{"ts":"2026-07-01T23:55:11.081Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Logged experiences for BPC-157 are almost all anecdotal (tier:anecdotal, weight ~0.3, quote_gated:true) and come from small Reddit/X/self-report sources. Positive: one user with elbow tendinopathy reported near-full return to climbing after 8 weeks (c21/s14); single L4-L5 herniation report of reduced radicular pain after 8 weeks + PT (c5); knee pain/chondromalacia improvement after 12 weeks allowing high-impact activity (c35/s30); gut-lining calming anecdote (c101/s83); combined BPC-157/TB-500 systemic/tendon healing report (c111/s93). Negative: nausea within two weeks leading to discontinuation (c6, c122, c124); severe adverse effects (dizziness, migraine, stomach issues, worsened symptoms) after low-dose BPC-157 + TB500 in user with TBI history (c34/s29). Scientific human safety data: one 2-person IV pilot up to 20 mg reported no adverse effects or biomarker changes (c3/s3). Long-term human safety unknown (c67/s1).","tokens_in":7216,"tokens_out":371,"cost":0,"prev":"e680ebc529f262bf068ae60edb4e0cde68eb4b20871641942586b2bf53ccb572","hash":"d58754ee09815c7fc2fbd06ace977ca2e71b68fbe1fc8310b59cfe1f6c8ce46c"},{"ts":"2026-07-01T23:55:16.948Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d58754ee09815c7fc2fbd06ace977ca2e71b68fbe1fc8310b59cfe1f6c8ce46c","hash":"c484e41b25343d1b14ca21b79110383b9746ca34a9be09742e81b110a5f6f9eb"},{"ts":"2026-07-03T00:01:41.427Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers: BPC-157 (bpc-157) has one explicit L4-L5 herniation anecdote (c5) plus general tendon/muscle preclinical work (c30, c76) and angiogenesis mechanism (c4). Recovery-stack-herniated-disc and bpc-ara-herniated-disc slugs exist but contain no active claims in this topology. TB-500 appears only in one positive anecdotal stack report (c111) with no herniated-disc specificity. ARA-290 (ara-290, ara-290-herniated-disc) and recovery-stack-intro slugs are present but empty of claims here. Interaction_risk / limitations claims (c120, c67) must be cited first: long-term human safety unknown, no dosing data, no established interactions.","tokens_in":7250,"tokens_out":390,"cost":0,"prev":"c484e41b25343d1b14ca21b79110383b9746ca34a9be09742e81b110a5f6f9eb","hash":"8ac43d7c35e72beffc7cb6ed997ef6911780467b00e189b4d1e637d234f3cbcc"},{"ts":"2026-07-03T00:01:47.680Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8ac43d7c35e72beffc7cb6ed997ef6911780467b00e189b4d1e637d234f3cbcc","hash":"4ab5a280404b5f16a9b620e4f673316d80ed14ed93b8e61c458e229f791e27ef"},{"ts":"2026-07-03T00:01:58.247Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"The catalogue lists a small number of anecdotal reports tied to herniated-disc or back-pain contexts: one Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 plus physical therapy (c5, bpc-157: tier=anecdotal). Several other Reddit self-test posts mention reduced back or knee pain after similar timelines but lack imaging follow-up. A separate anecdote notes nausea within two weeks leading to discontinuation (c6 / c122 / c124 / c126, same article). All such reports are explicitly labeled anecdotal, low-weight (0.3), and not evidence of safety or efficacy.","tokens_in":7246,"tokens_out":271,"cost":0,"prev":"4ab5a280404b5f16a9b620e4f673316d80ed14ed93b8e61c458e229f791e27ef","hash":"908b5c18a2a662ffd7a961f575d5da3ff10dd15c8047003544da0c379cd32cf9"},{"ts":"2026-07-03T00:02:20.341Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Logged good experiences (anecdotal tier, Reddit/X sources): elbow tendinopathy user returned to climbing after 8 weeks with near-full reported healing (c21, s14); reduced back/knee/radicular pain after 8 weeks with PT (c5, c22, s15, s17, s18); gut lining/inflammation calming in stack use (c101, s83); combined BPC-157/TB-500 tissue and tendon healing (c111, s93). Logged bad experiences (anecdotal tier): nausea within 2 weeks leading to discontinuation (c6, c122, c124, c126); severe adverse effects (dizziness, migraine, stomach issues, worsened symptoms) in TBI-history user after low-dose BPC-157+TB500 (c34, s29). Safety-first limitations: long-term human safety unknown (c67); human data sparse, mostly preclinical (c120, c66).","tokens_in":7226,"tokens_out":336,"cost":0,"prev":"908b5c18a2a662ffd7a961f575d5da3ff10dd15c8047003544da0c379cd32cf9","hash":"2368bc25200446d18a8b58457242c1dda7b04e3db34892f08e50a0c69a3aa46f"},{"ts":"2026-07-03T00:02:26.442Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"2368bc25200446d18a8b58457242c1dda7b04e3db34892f08e50a0c69a3aa46f","hash":"12549d03f9003b3f508cd98a29bb44100c257d6b15b6ae7ff6a21619376939b1"},{"ts":"2026-07-03T00:04:02.472Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers BPC-157 (bpc-157 slug) with one anecdotal claim for L4-L5 herniated disc (reduced radicular pain after 8 weeks + PT, c5) plus general tendon/muscle preclinical and anecdotal material. recovery-stack-herniated-disc, bpc-ara-herniated-disc, ara-290-herniated-disc and ara-290 slugs exist in the graph but contain no active claims in the provided topology. TB-500 (tb-500 slug) appears only in combined anecdotal claims (c111) not specific to disc herniation. recovery-stack-intro has no disc-specific claims listed.","tokens_in":7260,"tokens_out":307,"cost":0,"prev":"12549d03f9003b3f508cd98a29bb44100c257d6b15b6ae7ff6a21619376939b1","hash":"7aeecbabbb25b1e41cc3a54eb22556adfefa1e2d4a8a4c1927aa21874048e1d2"},{"ts":"2026-07-03T00:04:08.676Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7aeecbabbb25b1e41cc3a54eb22556adfefa1e2d4a8a4c1927aa21874048e1d2","hash":"aa8bf154e32ad055e1c15f5412683ab079618de642ea7d9a78fa6d617d0ea671"},{"ts":"2026-07-03T00:04:19.355Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"The catalogue records a small number of anecdotes for herniated-disc use. One user (L4-L5 herniation) reported reduced radicular pain after 8 weeks of BPC-157 plus physical therapy (global_id bpc-157:c5, tier:anecdotal). Separate nausea reports exist (global_id bpc-157:c6, c122, c124, c126, c128). All are labeled anecdotal, n=1, and carry low weight (0.3). No imaging-confirmed outcomes or controlled data appear. Herniated-disc recovery-stack and ara-290 articles are listed in the topology but contain no additional anecdotes in the provided excerpt.","tokens_in":7256,"tokens_out":271,"cost":0,"prev":"aa8bf154e32ad055e1c15f5412683ab079618de642ea7d9a78fa6d617d0ea671","hash":"f8af81a2b1e7807dfd055d28342f41acc62b54e4507f839592464bdc0664545e"},{"ts":"2026-07-03T00:04:53.156Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f8af81a2b1e7807dfd055d28342f41acc62b54e4507f839592464bdc0664545e","hash":"a1ecf0f1e108544d289d760a66338f6b761099a533690efd42321154ba926996"},{"ts":"2026-07-03T04:45:16.099Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"The catalogue covers BPC-157 (bpc-157 slug) with one herniated-disc anecdote (L4-L5 radicular pain reduction after 8 weeks + PT, c5, anecdotal tier, global_id bpc-157:c5) plus general tendon/muscle recovery claims and TB-500 combination anecdotes (c111). A dedicated recovery-stack-herniated-disc slug and bpc-ara-herniated-disc / ara-290-herniated-disc slugs exist but contain no populated claims in the provided topology. Limitations slot (c120) and long-term safety gap (c67) are present. No dosing, protocols, or treatment claims are included. Gaps: no ara-290 or TB-500 herniated-disc claims; no interaction_risk data for disc pathology; no human imaging outcomes; no stack synergy data for discs.","tokens_in":7273,"tokens_out":341,"cost":0,"prev":"a1ecf0f1e108544d289d760a66338f6b761099a533690efd42321154ba926996","hash":"67ec11aadf354bb3efde9d64c22364af155d54a0511245f218e82c2cc60568a3"},{"ts":"2026-07-03T04:45:23.837Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"67ec11aadf354bb3efde9d64c22364af155d54a0511245f218e82c2cc60568a3","hash":"1d03e17c76d5e9e466f7947846e4bcf72f18857adaeb57f85c91d33de156e440"},{"ts":"2026-07-03T04:45:36.404Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"The catalogue lists a small number of anecdotes under herniated-disc or back-pain contexts. One Reddit-style entry (global_id bpc-157:c5) describes reduced radicular pain after 8 weeks of BPC-157 plus PT in a single L4-L5 case. Several other anecdotal posts mention reduced back or knee pain after ~8 weeks but without imaging follow-up. One negative anecdote (global_id bpc-157:c6 and duplicates) reports nausea within two weeks leading to discontinuation. All such entries are explicitly labeled anecdotal (tier:anecdotal, weight 0.3) and are not tied to any controlled human data. The safety-first limitations claim (bpc-157:c120) and disclaimer (bpc-157:c65) appear first: human data remain sparse, long-term safety unknown, and no dosing or treatment advice is given.","tokens_in":7269,"tokens_out":294,"cost":0,"prev":"1d03e17c76d5e9e466f7947846e4bcf72f18857adaeb57f85c91d33de156e440","hash":"8f13c9d3d80c1164b1ac7e4668368e8168b081d76d0edf85f08563e2650eb682"},{"ts":"2026-07-03T04:45:59.347Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Logged experiences for BPC-157 are almost entirely anecdotal (tier: anecdotal, weight ~0.3). Positive reports include one user with elbow tendinopathy who returned to climbing after eight weeks describing the elbow as “almost 100 percent healed” (c21, s14) and multiple self-test posts noting reduced back or knee pain after eight weeks without imaging follow-up (c5, c22, s15, s17, s18). Additional anecdotes mention reduced radicular pain in L4-L5 herniation with PT (c5) and perceived gut-lining or tendon benefits when stacked (c101, c111). Negative reports center on one user who experienced nausea within two weeks and discontinued use (c6, c122–c130). All such reports are single-user, unverified, and explicitly labeled anecdotal. No human adverse-event data beyond the two-person 20 mg IV pilot (c3, s3) are catalogued; long-term safety remains unknown (c67). Marketing claims (c11) and quote-gated reviews (c12, c13, c26 etc.) are excluded from the safety-first ranking. No interaction-risk claims appear in the topology.","tokens_in":7245,"tokens_out":382,"cost":0,"prev":"8f13c9d3d80c1164b1ac7e4668368e8168b081d76d0edf85f08563e2650eb682","hash":"d850f18f7817215c18ecce73d3d0f49125bc839bc9f3662d16fe67b023c18bcf"},{"ts":"2026-07-03T04:46:07.064Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d850f18f7817215c18ecce73d3d0f49125bc839bc9f3662d16fe67b023c18bcf","hash":"05100ec3128d062eefc18cc9d4c24c604f9c851f9ead42ac66e9cab516e44dbc"},{"ts":"2026-07-03T05:04:59.790Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"The catalogue covers: BPC-157 (bpc-157) with one L4-L5 herniation anecdote reporting reduced radicular pain after 8 weeks with PT (global_id bpc-157:c5, tier anecdotal). A recovery-stack-herniated-disc slug and bpc-ara-herniated-disc / ara-290-herniated-disc slugs exist but contain no populated claims in the provided topology. TB-500 is catalogued separately with anecdotal claims for combined BPC-157/TB-500 tissue healing (global_id bpc-157:c111). No interaction_risk or limitations-slot claims specific to herniated discs appear. Gaps: no human clinical data, no dosing, no controlled evidence, no ara-290 claims populated, no safety/interaction data for stacks in disc pathology. The topology does not cover patient-specific factors, imaging confirmation, or medical diagnosis.","tokens_in":7279,"tokens_out":346,"cost":0,"prev":"05100ec3128d062eefc18cc9d4c24c604f9c851f9ead42ac66e9cab516e44dbc","hash":"5d9ab632e75695c1cc73766f085254fd6a3b43397746861533d8fffb4053a010"},{"ts":"2026-07-03T05:05:07.947Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"5d9ab632e75695c1cc73766f085254fd6a3b43397746861533d8fffb4053a010","hash":"4700613e6f523e6669d49d256c6cb5d5ced020989e123e61fbb09dfb4abc86b6"},{"ts":"2026-07-03T05:05:18.739Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"Catalogue records 1 explicit herniated-disc anecdote for BPC-157 (c5: L4-L5 user reported reduced radicular pain after 8 weeks with PT, n=1, tier=anecdotal, weight=0.3). Multiple other anecdotal claims exist (c6, c101, c111, c16, c21, c22, c23) but none are tied to disc herniation. No interaction_risk or limitations-slot claims appear for this specific combination. All anecdotes are low-weight and quote_gated:false except where noted.","tokens_in":7275,"tokens_out":234,"cost":0,"prev":"4700613e6f523e6669d49d256c6cb5d5ced020989e123e61fbb09dfb4abc86b6","hash":"7cf9bf885f779709fd9d59ecad6d951914c5be107b84e5cd3d9e851b70e4fbaa"},{"ts":"2026-07-03T05:05:41.998Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"From the catalogue: Good experiences logged are mostly anecdotal (tier: anecdotal). One Reddit user (elbow tendinopathy) reported returning to climbing after 8 weeks with the elbow described as “almost 100 percent healed” (c21, source s14). Several other self-test posts describe reduced back or knee pain after 8 weeks (c22, c5) with no imaging follow-up. One anecdote claims BPC-157 helped calm inflammation and rebuild gut lining (c101). One positive anecdotal report for combined BPC-157/TB-500 in systemic tissue and tendon healing (c111). Bad experiences: multiple duplicate entries of one user reporting nausea within two weeks and discontinuing (c6, c122–c132). Human safety data are limited to a 2-person pilot with no adverse effects reported short-term (c3); long-term safety is unknown (c67). All human data are sparse (c120). No interaction_risk claims logged.","tokens_in":7251,"tokens_out":330,"cost":0,"prev":"7cf9bf885f779709fd9d59ecad6d951914c5be107b84e5cd3d9e851b70e4fbaa","hash":"fe3a8e17a2bea8fe771f0c6fed892b34d377145335b8e14667b36e031871d189"},{"ts":"2026-07-03T05:05:49.826Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fe3a8e17a2bea8fe771f0c6fed892b34d377145335b8e14667b36e031871d189","hash":"db7f460bee1db81020d369106f6b2051ec0a3b7879696f678634699d40763369"},{"ts":"2026-07-03T05:11:24.006Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers: BPC-157 (bpc-157) and the recovery-stack-herniated-disc article; also references TB-500 (tb-500) and BPC/TB-500 combination anecdotes. Specific herniated-disc mentions include one Reddit anecdote of reduced radicular pain after 8 weeks of BPC-157 plus PT (bpc-157:c5) and general preclinical tendon/muscle healing data. No dedicated ara-290-herniated-disc or bpc-ara-herniated-disc evidence is present. Gaps: zero controlled human trials for disc herniation, no dosing, no long-term safety, no interaction data, and no coverage of other peptides or stacks beyond the listed slugs.","tokens_in":7289,"tokens_out":291,"cost":0,"prev":"db7f460bee1db81020d369106f6b2051ec0a3b7879696f678634699d40763369","hash":"7da19cecedbf37012dea0f15d9c7ac2e0ad93e15b701bf449892e5901ec87a48"},{"ts":"2026-07-03T05:11:31.386Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"7da19cecedbf37012dea0f15d9c7ac2e0ad93e15b701bf449892e5901ec87a48","hash":"11aaaae5d3248e507289ae2de814a35ec1bf74a336b19490bf3037403ab2f257"},{"ts":"2026-07-03T05:11:41.786Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"The catalogue records two herniated-disc anecdotes for BPC-157 (global_id bpc-157:c5 and recovery-stack-herniated-disc entries). Both are tier:anecdotal, weight 0.3, explicitly labeled n=1 self-reports with no imaging or controls. One positive report (reduced radicular pain after 8 weeks + PT) and several duplicate nausea/discontinuation reports. No higher-tier human data for herniated discs exists in the topology. Interaction_risk/limitations claims (c120, c67) rank first: long-term human safety unknown, no dosing guidance, sparse human evidence overall.","tokens_in":7285,"tokens_out":227,"cost":0,"prev":"11aaaae5d3248e507289ae2de814a35ec1bf74a336b19490bf3037403ab2f257","hash":"039e1e769e43d7a59ee68410779359813e552ed8d047a32587e1078d0a51a48d"},{"ts":"2026-07-03T05:12:02.652Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Scientific tier: one 2-person IV pilot (s3) reported no adverse effects or biomarker changes. Preclinical tier: consistent tendon/muscle/gut repair signals in rat models (s1, s11, s57) via angiogenesis and collagen pathways (c4). Anecdotal tier: positive self-reports include elbow tendinopathy return-to-climbing after 8 weeks (s14/c21), reduced back/knee pain (s15/s17/s18), and gut calming (s83/c101); negative self-reports include nausea within 2 weeks leading to discontinuation (c6, c122–c134). Long-term human safety unknown (c67). Marketing volume exists but is not evidence (c11). No interaction_risk claims present. Catalogue covers only logged sources; does not cover patient dosing, diagnosis, or personalized safety.","tokens_in":7257,"tokens_out":304,"cost":0,"prev":"039e1e769e43d7a59ee68410779359813e552ed8d047a32587e1078d0a51a48d","hash":"3a812c527daea1f54a2f86b5dabb7a34e4d5ff9fcad08a3309249a5fba995506"},{"ts":"2026-07-03T05:12:10.176Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"3a812c527daea1f54a2f86b5dabb7a34e4d5ff9fcad08a3309249a5fba995506","hash":"e61da06d321ed06f9d2414077d9afce342bcb580a8ceb20059350d2f78a77003"},{"ts":"2026-07-03T17:42:54.202Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers: BPC-157 (bpc-157) has one anecdotal claim (global_id bpc-157:c5) of reduced radicular pain after 8 weeks with PT in L4-L5 herniation (tier:anecdotal). Recovery-stack-herniated-disc and bpc-ara-herniated-disc list BPC-157 plus ARA-290 combinations under recovery-stack-intro; no controlled human data. TB-500 (tb-500) and ARA-290 (ara-290, ara-290-herniated-disc) appear in stack articles but carry only mechanistic or marketing claims. Interaction_risk / limitations claims (bpc-157:c120, c67) rank first: long-term human safety unknown; no dosing or protocol data. Gaps: no human RCTs for herniated-disc outcomes; no imaging follow-up; no interaction data with NSAIDs, steroids, or spine surgery; zero coverage of patient-specific factors (disc level, severity, comorbidities).","tokens_in":7291,"tokens_out":375,"cost":0,"prev":"e61da06d321ed06f9d2414077d9afce342bcb580a8ceb20059350d2f78a77003","hash":"28ca1dc0c0da3a025470c44cc7499b1283ac078b4d5e39ed16828db6adc70a7f"},{"ts":"2026-07-03T17:42:57.774Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"28ca1dc0c0da3a025470c44cc7499b1283ac078b4d5e39ed16828db6adc70a7f","hash":"4b4b7e8475fa9c82b2ce597668d14ff8bbe4b6a8334cbde442c694ee8dce62ff"},{"ts":"2026-07-03T17:43:04.953Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"Catalogue covers 30 anecdotal claims across sources. For herniated discs specifically: one Reddit-style anecdote (c5) reports reduced radicular pain after 8 weeks of BPC-157 with PT (L4-L5, n=1). Multiple duplicate nausea reports exist (c6, c122 and later duplicates). No controlled human data on disc herniation; all disc-related entries remain single-user, unverified anecdotes. Interaction_risk / limitations claims (c120, c67) rank first: long-term human safety unknown, no dosing guidance, evidence mix is preclinical + anecdotal only.","tokens_in":7287,"tokens_out":221,"cost":0,"prev":"4b4b7e8475fa9c82b2ce597668d14ff8bbe4b6a8334cbde442c694ee8dce62ff","hash":"0dff2aebeb785d340ca611e712dd7964798d026fd585e950fc08821ed7baf389"},{"ts":"2026-07-03T17:43:19.253Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Safety-first: long-term human safety data are absent (c67). Short-term pilot (two healthy adults, up to 20 mg IV) reported no adverse effects on vital signs or biomarkers (c3). Anecdotal nausea within two weeks leading to discontinuation appears in multiple logged entries (c6, c122, c124, c126, c128, c130, c132, c134, c136). Positive anecdotes include one user reporting reduced radicular pain after 8 weeks for L4-L5 herniation with PT (c5) and one user with elbow tendinopathy describing near-full return to climbing after 8 weeks (c21). Other anecdotes mention gut-lining calming (c101) and combined BPC-157/TB-500 tissue healing (c111). All human efficacy claims remain anecdotal or from uncontrolled pilots; no controlled human outcome data are catalogued. Preclinical studies (rat/mouse tendon, muscle, gut) consistently show healing signals but cannot be extrapolated to people (c30, c76).","tokens_in":7260,"tokens_out":361,"cost":0,"prev":"0dff2aebeb785d340ca611e712dd7964798d026fd585e950fc08821ed7baf389","hash":"9dde9f96e2808f2670a0c666ad3b09f5f35ea2845f32032f6109b5e16423efa5"},{"ts":"2026-07-03T17:43:23.687Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9dde9f96e2808f2670a0c666ad3b09f5f35ea2845f32032f6109b5e16423efa5","hash":"f7b31f403064c3193572b71ae9dd390755a10c0b445ea591dfe581d8aa5875a7"},{"ts":"2026-07-04T22:08:58.897Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"The catalogue covers two dedicated herniated-disc recovery stacks (recovery-stack-herniated-disc and bpc-ara-herniated-disc) plus standalone BPC-157, TB-500, and ARA-290 articles. Evidence mix: predominantly preclinical animal data plus anecdotal reports. No human RCTs for disc herniation. BPC-157 shows rat tendon/muscle healing via angiogenesis and collagen pathways (preclinical tier). One Reddit anecdote (tier:anecdotal) reports reduced radicular pain after 8 weeks BPC-157 + PT in L4-L5 herniation. TB-500 is referenced in combined anecdotal claims for systemic tissue healing. ARA-290 appears in a specific bpc-ara-herniated-disc stack article. Interaction_risk / limitations claims state long-term human safety unknown, no established dosing, and catalogue provides no treatment advice. Gaps: no human imaging-confirmed disc healing data, no controlled trials, unknown drug interactions, unknown effects on healthy tissue angiogenesis.","tokens_in":7294,"tokens_out":355,"cost":0,"prev":"f7b31f403064c3193572b71ae9dd390755a10c0b445ea591dfe581d8aa5875a7","hash":"e2ebe445749cb2a03e9d695d458d4ea20a6da134d128269f3ac566041ee55929"},{"ts":"2026-07-04T22:09:02.809Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e2ebe445749cb2a03e9d695d458d4ea20a6da134d128269f3ac566041ee55929","hash":"910dfbe47eed648edac5e9f26f70be08625c1d97f2a443005ed107b764fb7c45"},{"ts":"2026-07-04T22:09:09.974Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"Catalogue covers BPC-157 only. One anecdotal claim exists for herniated disc: c5 (global_id bpc-157:c5) states one Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 plus PT (anecdotal, n=1, tier=anecdotal, weight=0.3). No other herniated-disc anecdotes appear for BPC-157 or other slugs. Multiple nausea anecdotes exist (e.g., c6, c122 and duplicates) but none link to disc issues. Safety-first claims appear first: c120 (limitations slot) and c67 (long-term safety unknown) rank ahead of any who_claims_what volume. All disc-related anecdotes are low-weight, quote_gated=false, and explicitly separated from human or preclinical evidence.","tokens_in":7290,"tokens_out":297,"cost":0,"prev":"910dfbe47eed648edac5e9f26f70be08625c1d97f2a443005ed107b764fb7c45","hash":"67bea1b76ea6571429e209f03a80bced9628f123ad214da6505fd75735a42bfb"},{"ts":"2026-07-04T22:09:23.589Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Good experiences logged: one Reddit user with elbow tendinopathy reported return to climbing after eight weeks and described the elbow as “almost 100 percent healed” (anecdotal). Several self-test posts describe reduced back or knee pain after eight weeks (anecdotal, no imaging). One user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1). Additional anecdotes mention calming inflammation and gut-lining repair, and positive combined use with TB-500 for tendon healing (all anecdotal tier). Bad experiences logged: repeated entries of one user reporting nausea within two weeks and discontinuing BPC-157 (anecdotal, n=1). No human adverse-effect data beyond the two-person pilot (no adverse effects reported) and no long-term safety data exist. Marketing volume and quote-gated claims (c12, c13, c16, c17, c20, c21, c26, c31, c37, c42, c43, c49, c50, c52, c77, c79, c80, c51) are lower-confidence and listed after interaction/limitations claims.","tokens_in":7265,"tokens_out":409,"cost":0,"prev":"67bea1b76ea6571429e209f03a80bced9628f123ad214da6505fd75735a42bfb","hash":"b85a730b2ad8855defee86e1f5f9788565e8c36af4c7a14bdda123e3b77357b4"},{"ts":"2026-07-04T22:09:27.469Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"b85a730b2ad8855defee86e1f5f9788565e8c36af4c7a14bdda123e3b77357b4","hash":"f637b6cdd908be4f07d3d48d6577c3faf95710ba68d350a04649202ab5e44b27"},{"ts":"2026-07-06T02:31:08.025Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers BPC-157 (bpc-157, recovery-stack-herniated-disc, bpc-ara-herniated-disc) with one L4-L5 herniation anecdote (reduced radicular pain after 8 weeks + PT) and preclinical tendon/muscle models. TB-500 appears in combined anecdotal claims for systemic/tendon healing. ARA-290 is listed in herniated-disc stack slugs but has no claims or data in the provided topology. Recovery-stack-intro provides general framing only. Gaps: no human trials for disc herniation, no dosing data, no interaction data, no long-term safety, and no ARA-290 evidence.","tokens_in":7304,"tokens_out":297,"cost":0,"prev":"f637b6cdd908be4f07d3d48d6577c3faf95710ba68d350a04649202ab5e44b27","hash":"be095fe9749c67946e22d53944ce1f7d69cdbbb4419240fe4222eb04bafa1a47"},{"ts":"2026-07-06T02:31:15.313Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"be095fe9749c67946e22d53944ce1f7d69cdbbb4419240fe4222eb04bafa1a47","hash":"07cf64ab1b997ba3750cf9502330815d8313be26a184f1d2cd31ff9fb8040448"},{"ts":"2026-07-06T02:31:30.443Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"Catalogue covers one direct herniated-disc anecdote: c5 (bpc-157) — one Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 plus PT (anecdotal, n=1, tier=anecdotal, weight=0.3). Multiple nausea reports (c6, c122–c140) exist as negative anecdotes (n=1 each). No other herniated-disc-specific anecdotes are catalogued in the provided slugs. Interaction_risk/limitations claims (c120) and disclaimer (c65) rank first per safety-first rule.","tokens_in":7300,"tokens_out":243,"cost":0,"prev":"07cf64ab1b997ba3750cf9502330815d8313be26a184f1d2cd31ff9fb8040448","hash":"d70c4669cf04b57775e2f3f3a4e9392f1c60490e83aae9709debef86e99ad342"},{"ts":"2026-07-06T02:31:57.519Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Good experiences logged (anecdotal tier, all from Reddit or similar self-reports): reduced radicular pain after 8 weeks in one L4-L5 herniation case with PT (c5); one user described elbow tendinopathy as “almost 100 percent healed” and returned to climbing after 8 weeks (s14, cross-referenced in s9/s13); several self-test posts report reduced back or knee pain after 8 weeks without imaging follow-up (s15, s17, s18); anecdotal gut-lining and inflammation calming when stacked (c101); positive combined BPC-157/TB-500 tissue/tendon healing reports (c111). Bad experiences logged (anecdotal tier): multiple duplicate entries of one user reporting nausea within two weeks and discontinuing (c6, c122, c124, c126, c128, c130, c132, c134, c136, c138, c140). Human safety data are limited to a 2-person IV pilot showing no adverse effects on vital signs or biomarkers (c3). Long-term human safety unknown (c67). No interaction_risk or limitations-slot claims present in the provided topology.","tokens_in":7278,"tokens_out":388,"cost":0,"prev":"d70c4669cf04b57775e2f3f3a4e9392f1c60490e83aae9709debef86e99ad342","hash":"68fcc154ec10850dbb7dcac37bb5cbd9fac2a62cf31b5cdbe56099e22d824909"},{"ts":"2026-07-06T02:32:07.603Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"68fcc154ec10850dbb7dcac37bb5cbd9fac2a62cf31b5cdbe56099e22d824909","hash":"4819d9b3a9add925b75331069a621de2302ff2032dcab01400ccee0cc05062cf"},{"ts":"2026-07-06T03:07:45.791Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"The catalogue covers BPC-157 (bpc-157) with one anecdotal report of reduced radicular pain after 8 weeks in L4-L5 herniation plus physical therapy (global_id bpc-157:c5). It also covers a recovery-stack-herniated-disc article and a bpc-ara-herniated-disc article that include BPC-157 combined with TB-500 (anecdotal positive for systemic tissue and tendon healing, global_id bpc-157:c111) and separate ARA-290 coverage (ara-290, ara-290-herniated-disc). TB-500 appears in the recovery stack context. No human clinical data for herniated discs are catalogued; all human-tier claims are limited to a 2-person IV safety pilot (global_id bpc-157:c3) and reviews noting sparse human evidence. Limitations and interaction_risk claims are placed first per safety-first ranking (global_id bpc-157:c120, c67).","tokens_in":7304,"tokens_out":426,"cost":0,"prev":"4819d9b3a9add925b75331069a621de2302ff2032dcab01400ccee0cc05062cf","hash":"22e04e086801287ce6108e6734c4ca41e797992621f8608915feae5dc4ffba80"},{"ts":"2026-07-06T03:07:50.381Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"22e04e086801287ce6108e6734c4ca41e797992621f8608915feae5dc4ffba80","hash":"7f3d999ba5dd054d5383874b93711730448a2efd2f4313f19b0a568fe3c48d69"},{"ts":"2026-07-06T03:07:59.034Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"The catalogue lists a small number of herniated-disc anecdotes for BPC-157. One user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 plus physical therapy (anecdotal, n=1). Several self-test posts mention reduced back or knee pain after eight weeks but include no imaging follow-up. One user reported nausea within two weeks and discontinued use (anecdotal, n=1). All are labeled anecdotal and low-weight. No controlled human data or imaging-confirmed outcomes for disc herniation appear in the ledger. Safety-first limitations (c120) and unknown long-term effects (c67) are noted before any who_claims_what entries.","tokens_in":7300,"tokens_out":252,"cost":0,"prev":"7f3d999ba5dd054d5383874b93711730448a2efd2f4313f19b0a568fe3c48d69","hash":"2a624a12779d62097db2f00d625c74be1ee7af1baa1629bf9babd842d954e66d"},{"ts":"2026-07-06T03:08:15.250Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"From the ledger: good experiences are limited to one Reddit anecdote of reduced radicular pain after 8 weeks in L4-L5 herniation with PT (c5) and general Reddit reports of reduced back/knee pain or return to activity after ~8 weeks (no imaging). Bad experiences include repeated entries of one user reporting nausea within two weeks and discontinuing use (c6, c122, c124, c126, c128, c130, c132, c134, c136, c138, c140, c142). No interaction_risk claims appear. All human data remain very small; long-term safety unknown (c67). Preclinical work shows consistent tendon/muscle/gut repair signals in animals but cannot be applied to people (c66). Marketing volume exists but is not evidence (c11).","tokens_in":7283,"tokens_out":267,"cost":0,"prev":"2a624a12779d62097db2f00d625c74be1ee7af1baa1629bf9babd842d954e66d","hash":"606783433e74e60a1c3927206954d3bfa0b545b21c8134ec6fae502dc00f695c"},{"ts":"2026-07-06T03:08:19.395Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"606783433e74e60a1c3927206954d3bfa0b545b21c8134ec6fae502dc00f695c","hash":"db600b5ae7ee8df80ed29990c9e969bace4ade00f8e3328f91366e6e13dc3ddf"},{"ts":"2026-07-07T03:41:44.846Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers: BPC-157 (bpc-157) with one anecdotal report of reduced radicular pain after 8 weeks in L4-L5 herniation (global_id bpc-157:c5, tier anecdotal); BPC-157 + TB-500 combinations noted in general tissue/tendon anecdotes (global_id bpc-157:c111); recovery-stack-herniated-disc and bpc-ara-herniated-disc slugs exist but supply only structural titles with no populated claims. Safety/limits claims present: long-term human safety unknown (global_id bpc-157:c67), human data sparse and mostly preclinical (global_id bpc-157:c120), marketing volume exists separate from evidence (global_id bpc-157:c11). No interaction_risk claims populated for disc herniation stacks.","tokens_in":7308,"tokens_out":402,"cost":0,"prev":"db600b5ae7ee8df80ed29990c9e969bace4ade00f8e3328f91366e6e13dc3ddf","hash":"c3ba231d7c8ff4fa5cf42b85fecd8ebe8d2abb8d1618e58ad7486a2c2c43eb6e"},{"ts":"2026-07-07T03:41:45.832Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c3ba231d7c8ff4fa5cf42b85fecd8ebe8d2abb8d1618e58ad7486a2c2c43eb6e","hash":"c6e70ca27d940d3ccc299e916e5bbcadc0ad83c37228298a6b479c23d02af963"},{"ts":"2026-07-07T03:41:51.941Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"The catalogue lists exactly two herniated-disc anecdotes for BPC-157: (1) one Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 plus PT (global_id bpc-157:c5, tier=anecdotal, weight=0.3); (2) one user reported nausea within two weeks and discontinued (global_id bpc-157:c6, tier=anecdotal, weight=0.3). No other herniated-disc anecdotes appear in any of the listed slugs. All other claims in the topology are mechanistic, preclinical, human safety data, or marketing volume. Limitations slot (global_id bpc-157:c120) is cited first per safety-first rule.","tokens_in":7304,"tokens_out":290,"cost":0,"prev":"c6e70ca27d940d3ccc299e916e5bbcadc0ad83c37228298a6b479c23d02af963","hash":"4f70725fb84b5a0d7a48a776c17ff60f930a023e06bbe86fc74f646d17fd9e4b"},{"ts":"2026-07-07T03:42:04.212Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Logged experiences for BPC-157 are sparse and split by tier. Scientific tier: one 2025 pilot (s3) gave up to 20 mg IV to two healthy adults and reported no adverse effects on vital signs, biomarkers, or subjective reports (c3). All other human data are limited to three small uncontrolled pilots or case reports; reviews (s19, s20, s27) state human evidence remains too small and uncontrolled for conclusions. Preclinical tier: 31 animal/lab studies (Croatian group) report consistent tendon, muscle, ligament, and gut-lining healing via angiogenesis and collagen pathways (s1, s11, s57). Anecdotal tier: 21 Reddit posts + 1 X post. Positive anecdotes include one user with elbow tendinopathy who returned to climbing after 8 weeks describing the elbow as “almost 100 percent healed” (s14) and several self-reports of reduced back or knee pain after 8 weeks of use (s15, s17, s18). Negative anecdotes include repeated entries of one user who experienced nausea within two weeks and discontinued (c6, c122–c144). Other anecdotes mention perceived gut-lining or combined BPC-157/TB-500 benefits but carry no imaging or controlled follow-up. No interaction-risk claims appear in the ledger. Long-term human safety data are absent (c67).","tokens_in":7284,"tokens_out":416,"cost":0,"prev":"4f70725fb84b5a0d7a48a776c17ff60f930a023e06bbe86fc74f646d17fd9e4b","hash":"736f8b2bf85eb3ed6c97a427be2b2455c0b43df66851a1e195d0f4fe25fc3924"},{"ts":"2026-07-07T03:42:04.679Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"736f8b2bf85eb3ed6c97a427be2b2455c0b43df66851a1e195d0f4fe25fc3924","hash":"33fe0bab451a59fa45def1549e119d4cee6d4020e7a197f8efb76fea6e55829e"},{"ts":"2026-07-07T03:43:19.061Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers BPC-157 (bpc-157) with one direct herniated-disc anecdote (c5: L4-L5 user reported reduced radicular pain after 8 weeks + PT) plus general tendon/muscle repair claims from rat studies (c30, c76). Recovery-stack-herniated-disc and bpc-ara-herniated-disc slugs exist but contain no active claims. TB-500 (tb-500) and ARA-290 (ara-290) have no herniated-disc entries. No interaction_risk or limitations-slot claims on disc-specific stacks are present.","tokens_in":7311,"tokens_out":292,"cost":0,"prev":"33fe0bab451a59fa45def1549e119d4cee6d4020e7a197f8efb76fea6e55829e","hash":"ef0a58db13b387bd39adc238bf9558228bc3b8ea1b8c16b3a0ecb6a6c8adc20a"},{"ts":"2026-07-07T03:43:19.577Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ef0a58db13b387bd39adc238bf9558228bc3b8ea1b8c16b3a0ecb6a6c8adc20a","hash":"6eb79414ae8b04be61f83d6b55339b1904e65ae7c7b6b6a9f2809e0fc7b498e6"},{"ts":"2026-07-07T03:43:26.265Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"Catalogue covers one L4-L5 herniated-disc anecdote under BPC-157 (c5: reduced radicular pain after 8 weeks + PT, n=1, tier=anecdotal, weight=0.3) plus multiple duplicate nausea reports (c6, c122–c146: discontinued within two weeks, n=1 each, tier=anecdotal). All other herniated-disc material in the topology is either preclinical or general limitations. No interaction_risk claims exist for disc conditions. No other slugs add herniated-disc anecdotes.","tokens_in":7307,"tokens_out":326,"cost":0,"prev":"6eb79414ae8b04be61f83d6b55339b1904e65ae7c7b6b6a9f2809e0fc7b498e6","hash":"73d51596d46a3ccee7283db1d8cb2150e816b17df151d86df0bcbfa1360aa202"},{"ts":"2026-07-07T03:43:39.905Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Safety-first: No interaction_risk or limitations-slot claims exist on combinations or adverse events beyond the known gaps. Human safety data are limited to one 2-person pilot with no adverse effects reported (c3). Long-term safety and side-effect profile in humans is unknown (c67). Evidence mix is predominantly preclinical and anecdotal; human data are sparse (c120). \n\nGood experiences (anecdotal tier, Reddit/X sources): One user with elbow tendinopathy reported return to climbing after 8 weeks with “almost 100 percent healed” elbow (s14). Several self-test posts describe reduced back or knee pain after 8 weeks (s15, s17, s18). One user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 plus PT (c5). Anecdotal reports of calmed inflammation and gut-lining rebuilding (c101) and positive tissue/tendon healing when combined with TB-500 (c111). \n\nBad experiences (anecdotal tier, Reddit sources): Multiple duplicate entries state one user reported nausea within two weeks and discontinued BPC-157 (c6, c122, c124, c126, c128, c130, c132, c134, c136, c138, c140, c142, c144, c146). \n\nPreclinical tier (animal/lab sources): Consistent healing signals in rat/mouse tendon, muscle, and gut models (s1, s11, s57, s58, s25). \n\nAll human claims are from small pilots or case reports with no controls; larger controlled trials are called for (s19, s20, s24, s27).","tokens_in":7287,"tokens_out":572,"cost":0,"prev":"73d51596d46a3ccee7283db1d8cb2150e816b17df151d86df0bcbfa1360aa202","hash":"421bf7c86f6bba266c405f4350682a1e912ea9ce3cdd6ad4cb8f095f86d21ed9"},{"ts":"2026-07-07T03:43:40.590Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"421bf7c86f6bba266c405f4350682a1e912ea9ce3cdd6ad4cb8f095f86d21ed9","hash":"60d2dc9615a558fdc29925cc0326d5db52891b837826d0854fa1fa1544e5ddc2"},{"ts":"2026-07-07T03:44:05.649Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"The catalogue covers BPC-157 (bpc-157 article) with one herniated-disc anecdote (L4-L5 radicular pain reduced after 8 weeks + PT, c5) and mentions of BPC-157/TB-500 combo anecdotes for tendon/tissue healing (c111). It also lists recovery-stack-herniated-disc and bpc-ara-herniated-disc slugs but contains no detailed claims on stacks, ARA-290, or TB-500 specifically for herniated discs. Safety-first claims are present: long-term human safety unknown (c67), no dosing or treatment recommendations (c120), and the evidence mix is predominantly preclinical/anecdotal with sparse human data.","tokens_in":7316,"tokens_out":297,"cost":0,"prev":"60d2dc9615a558fdc29925cc0326d5db52891b837826d0854fa1fa1544e5ddc2","hash":"d006286cf47a769dd7a85d4585d314419fa6c9171fb5c98282421f3b9a9a2d78"},{"ts":"2026-07-07T03:44:06.066Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d006286cf47a769dd7a85d4585d314419fa6c9171fb5c98282421f3b9a9a2d78","hash":"96a18ad0e2efcc3a397bfcb8741599fa08c3bb29b6da4234e27f8a37d11a3841"},{"ts":"2026-07-07T03:44:11.889Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"The catalogue contains one explicit herniated-disc anecdote for BPC-157: a single Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 plus physical therapy (global_id bpc-157:c5, tier:anecdotal). All other herniated-disc-related anecdotes in the topology are either gut-focused, tendon/muscle-focused, or nausea reports; none are imaging-confirmed disc claims. The catalogue explicitly labels these as anecdotal (tier:anecdotal, weight 0.3) and states evidence mix is predominantly preclinical and anecdotal with sparse human data (bpc-157:c120). No interaction_risk or limitations-slot claims appear in the provided herniated-disc slugs.","tokens_in":7312,"tokens_out":280,"cost":0,"prev":"96a18ad0e2efcc3a397bfcb8741599fa08c3bb29b6da4234e27f8a37d11a3841","hash":"a14cdcd3448d90aacff7711763ab6423d14bae66fab3b870e09fb9e31d9a4540"},{"ts":"2026-07-07T03:44:21.935Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"From the BPC-157 topology, good experiences are limited to one Reddit anecdote (c5) of reduced radicular pain after 8 weeks in a herniated-disc case (anecdotal, n=1) and several other Reddit self-test posts describing reduced back/knee pain or return to activity (e.g., elbow tendinopathy described as “almost 100 percent healed” after eight weeks). Bad experiences include multiple identical entries (c6, c122–c148) of one user reporting nausea within two weeks and discontinuing use (anecdotal, n=1). No human safety or efficacy claims beyond the two-person IV pilot (c3) exist; long-term safety is unknown (c67). All human claims are low-volume; most evidence is preclinical or marketing (c11).","tokens_in":7294,"tokens_out":262,"cost":0,"prev":"a14cdcd3448d90aacff7711763ab6423d14bae66fab3b870e09fb9e31d9a4540","hash":"36007e08df1b3020ae2211eb950dcfdc535921d6ff5cd7f18ad011f9bc4bbffb"},{"ts":"2026-07-07T03:44:22.528Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"36007e08df1b3020ae2211eb950dcfdc535921d6ff5cd7f18ad011f9bc4bbffb","hash":"0acd26dad7950e568db8a03f7ea8fc3d4955c91d5d2b2a7d5320f1867a24d07f"},{"ts":"2026-07-07T03:46:13.585Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers: BPC-157 (bpc-157) with one anecdotal report of reduced radicular pain after 8 weeks in L4-L5 herniation when used with PT (c5); recovery-stack-herniated-disc and bpc-ara-herniated-disc slugs exist but contain no active claims; TB-500 appears only in one anecdotal combined-use claim (c111). No interaction_risk or limitations-slot claims specific to disc herniation are present. Gaps: no controlled human data on any peptide for herniated discs; no ara-290 or recovery-stack claims populated for this condition; long-term safety, dosing, and imaging outcomes unknown.","tokens_in":7326,"tokens_out":300,"cost":0,"prev":"0acd26dad7950e568db8a03f7ea8fc3d4955c91d5d2b2a7d5320f1867a24d07f","hash":"e7270658b1c9fbff569609ab8468836cc8a393194cc8e1cf389668dd5cf75ef4"},{"ts":"2026-07-07T03:46:14.076Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e7270658b1c9fbff569609ab8468836cc8a393194cc8e1cf389668dd5cf75ef4","hash":"bc292219bd8121c8ee53e0e87fe927ecda880d9589730954a76c54546f206a21"},{"ts":"2026-07-07T03:46:20.560Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"Catalogue covers 30 anecdotal claims total for BPC-157. One specific herniated-disc anecdote (global_id bpc-157:c5) states: 'One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (anecdotal, n=1)'. Additional anecdotal claims exist for tendon/muscle/gut contexts but are not specific to discs. No interaction_risk or limitations-slot claims flag safety issues for this use-case. Multiple duplicate nausea anecdotes (c6, c122–c150) are recorded as single-user reports. All anecdotes are tier 'anecdotal' weight 0.3 and explicitly separated from human or preclinical data.","tokens_in":7322,"tokens_out":252,"cost":0,"prev":"bc292219bd8121c8ee53e0e87fe927ecda880d9589730954a76c54546f206a21","hash":"d0e36cad67bd165f24bb52470e6fe488ee63e1d17e8454e72545f22334350f01"},{"ts":"2026-07-07T03:46:35.458Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"From the topology: Good experiences logged are all anecdotal (tier: anecdotal, weight 0.3): one Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks with PT (c5); multiple self-test posts describe reduced back or knee pain after eight weeks but without imaging follow-up (s15, s17, s18); one user with elbow tendinopathy reported return to climbing after eight weeks and described the elbow as “almost 100 percent healed” (s14); anecdotal claims of gut-lining healing and reduced inflammation (c101) and combined BPC-157/TB-500 tissue/tendon healing (c111). Bad experiences logged: repeated anecdotal reports (tier: anecdotal, weight 0.3) of nausea within two weeks leading to discontinuation (c6, c122, c124, c126, c128, c130, c132, c134, c136, c138, c140, c142, c144, c146, c148, c150). No interaction_risk or limitations-slot claims on combinations or safety interactions are present in the catalogue. Human safety data are limited to one two-person IV pilot showing no short-term adverse effects (c3). Long-term human safety unknown (c67). All human data are sparse; most evidence is preclinical or anecdotal.","tokens_in":7299,"tokens_out":430,"cost":0,"prev":"d0e36cad67bd165f24bb52470e6fe488ee63e1d17e8454e72545f22334350f01","hash":"53ed5b8acb0ef8cb2f7eb3f71df9aee037e1a3dc7157b87950695d44b6d2ab37"},{"ts":"2026-07-07T03:46:35.995Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"53ed5b8acb0ef8cb2f7eb3f71df9aee037e1a3dc7157b87950695d44b6d2ab37","hash":"b827b4afa9e3bc0c7bc0255c1f9751938d9a1ce25e1200914574332722024a1c"},{"ts":"2026-07-07T03:48:40.606Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers BPC-157 (slug bpc-157) for herniated-disc context via one anecdotal claim (c5) of reduced radicular pain after 8 weeks with PT (L4-L5, n=1, tier:anecdotal). It also covers recovery-stack-herniated-disc and bpc-ara-herniated-disc stacks that include BPC-157 plus TB-500 (anecdotal positive for combined use in systemic/tendon healing at c111) and ARA-290 (slugs ara-290-herniated-disc, ara-290). TB-500 appears in recovery stacks. Safety-first limitations claim c120 (limitations slot) and long-term safety unknown claim c67 are present. No human controlled data for disc herniation; all disc-specific evidence is anecdotal or preclinical. Gaps: no interaction_risk data, no dosing, no imaging-confirmed outcomes, no human trials for herniated discs.","tokens_in":7335,"tokens_out":357,"cost":0,"prev":"b827b4afa9e3bc0c7bc0255c1f9751938d9a1ce25e1200914574332722024a1c","hash":"39436914acf0e3a76874732fd07fc863e4cf9749b65f18193c278073d2073def"},{"ts":"2026-07-07T03:48:41.246Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"39436914acf0e3a76874732fd07fc863e4cf9749b65f18193c278073d2073def","hash":"69656a1d5a5589388dc1b541d93c01ecd04a218722025116640dc5c82bd25035"},{"ts":"2026-07-07T03:48:48.294Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"Catalogue covers herniated-disc anecdotes in bpc-157 and recovery-stack-herniated-disc: one Reddit-style report (c5) of reduced radicular pain after 8 weeks BPC-157 + PT (L4-L5, n=1, anecdotal tier). Multiple nausea/discontinuation reports appear as low-weight anecdotes (c6, c122 and duplicates). All such claims sit in 'anecdotal' tier, weight 0.3, explicitly separated from human (weight 0.8) or preclinical (weight 0.5) tiers. Limitations slot (c120) states evidence mix is 'predominantly preclinical and anecdotal; human data are sparse.' No interaction_risk claims are present for this context. Quote-gated claims are absent from the herniated-disc anecdotes.","tokens_in":7331,"tokens_out":263,"cost":0,"prev":"69656a1d5a5589388dc1b541d93c01ecd04a218722025116640dc5c82bd25035","hash":"6ff88385b1d265ee31993976fb671a65a4f7defa1a2508d684831f68fb11af6f"},{"ts":"2026-07-07T03:48:58.192Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Good experiences logged (anecdotal tier only): one Reddit user with elbow tendinopathy reported returning to climbing after eight weeks with the elbow described as “almost 100 percent healed” (s14); several self-test posts described reduced back or knee pain after eight weeks (s15, s17, s18); one user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 with PT (c5); anecdotal reports of calmed inflammation and gut-lining rebuilding (c101); anecdotal positive for combined BPC-157/TB-500 in systemic tissue and tendon healing (c111). Bad experiences logged (anecdotal tier only): one user reported nausea within two weeks and discontinued BPC-157 (c6, c122 and duplicate entries c124–c152). No human efficacy claims are ranked above anecdotal; all positive reports are self-reported without imaging or controls. Safety-first limitations claims (c120, c67) state long-term human safety data are absent and the catalogue contains no dosing or interaction data.","tokens_in":7308,"tokens_out":334,"cost":0,"prev":"6ff88385b1d265ee31993976fb671a65a4f7defa1a2508d684831f68fb11af6f","hash":"cebcb45e7f969b8e578f838ab4193b439c5b75c670ba17ff9255e4cdd36c464b"},{"ts":"2026-07-07T03:48:58.604Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"cebcb45e7f969b8e578f838ab4193b439c5b75c670ba17ff9255e4cdd36c464b","hash":"b138220b773936405eed93c14e4d22d82a090f26f113fd0827b9ce4e326f3262"},{"ts":"2026-07-07T03:50:43.307Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers BPC-157 (slug:bpc-157) with one anecdotal report of reduced radicular pain in L4-L5 herniation after 8 weeks with PT (global_id bpc-157:c5, tier:anecdotal) plus general preclinical tendon/muscle healing claims (global_id bpc-157:c30, c76). Recovery-stack-herniated-disc and bpc-ara-herniated-disc slugs exist but contain no populated claims in the provided topology. TB-500 (slug:tb-500) is referenced only via one anecdotal positive for combined BPC-157/TB-500 in tendon healing (global_id bpc-157:c111, tier:anecdotal). No ARA-290 or recovery-stack-intro claims address herniated discs. Interaction_risk / limitations claims (global_id bpc-157:c120, c67, c66) are cited first: long-term human safety unknown, no dosing/protocol, sparse human data, source monoculture problem. No stack is described or recommended.","tokens_in":7337,"tokens_out":456,"cost":0,"prev":"b138220b773936405eed93c14e4d22d82a090f26f113fd0827b9ce4e326f3262","hash":"d4ae953e9e4266fd5add2d95516dee0f0cc02344c9fd967c5ea1d416bb06681a"},{"ts":"2026-07-07T03:50:43.832Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"d4ae953e9e4266fd5add2d95516dee0f0cc02344c9fd967c5ea1d416bb06681a","hash":"3b8679dcf1d5b7bae7daf32d3ea2d55fd4950c7643803a4c3e359c00e4045b6b"},{"ts":"2026-07-07T03:50:49.801Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"Catalogue covers 1 explicit herniated-disc anecdote (L4-L5 user reported reduced radicular pain after 8 weeks BPC-157 + PT; global_id bpc-157:c5). All other anecdotes are non-specific (elbow, knee, back pain without imaging) or gut/tendon related. Safety-first limitations slot (bpc-157:c120) states evidence mix is predominantly preclinical/anecdotal with sparse human data; no dosing or treatment claims. Multiple duplicate nausea anecdotes exist but remain low-weight. Quote-gated reviews note limited human evidence.","tokens_in":7333,"tokens_out":231,"cost":0,"prev":"3b8679dcf1d5b7bae7daf32d3ea2d55fd4950c7643803a4c3e359c00e4045b6b","hash":"4fcb0059065849e8be6ff6713c076cc52dbe256123f83aceddf9198e784b08f8"},{"ts":"2026-07-07T03:51:02.014Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Logged good experiences for BPC-157 are all anecdotal and low-weight: one Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks with PT (c5); other Reddit self-test posts claim reduced back or knee pain or return to climbing after ~8 weeks with the elbow described as “almost 100 percent healed” (s14, s15, s17, s18); anecdotal posts also mention gut-lining calming or combined BPC-157/TB-500 tissue/tendon healing (c101, c111). Bad experiences logged are limited to repeated identical entries of one user reporting nausea within two weeks and discontinuing (c6, c122–c154). No interaction_risk or limitations-slot claims appear in the provided topology. All human data remain sparse (two-person IV pilot with no adverse effects reported in that small sample, c3); most evidence is preclinical (rat/mouse healing models) or anecdotal.","tokens_in":7316,"tokens_out":312,"cost":0,"prev":"4fcb0059065849e8be6ff6713c076cc52dbe256123f83aceddf9198e784b08f8","hash":"a82360867dc82f0e941f2dd3bcb17969ab88c1c7dbd12321b297bbe851c95e9e"},{"ts":"2026-07-07T03:51:02.594Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a82360867dc82f0e941f2dd3bcb17969ab88c1c7dbd12321b297bbe851c95e9e","hash":"0654b0bc35284feb32213059e3f1c692847658e30bbb43c2e1524a3aaa105cf8"},{"ts":"2026-07-07T04:07:21.752Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers BPC-157 (angiogenesis/collagen/fibroblast mechanisms in animal tendon/muscle/gut models; 2 human pilot safety reports) plus TB-500 (anecdotal combined use with BPC-157 for systemic tissue/tendon healing) and limited ARA-290 mentions. Herniated-disc-specific entries exist under recovery-stack-herniated-disc and bpc-ara-herniated-disc. One anecdotal claim (c5) notes reduced radicular pain after 8 weeks BPC-157 + PT in L4-L5 herniation. Safety-first limitations (c120, c67) and interaction_risk slots are present. Gaps: no human herniated-disc trials, no dosing data, no long-term safety, unknown interactions with disc medications or conditions, no ARA-290 or TB-500 herniated-disc studies catalogued. Needs_user_info: disc level(s), symptom duration, current treatments/medications, imaging status, other health conditions.","tokens_in":7346,"tokens_out":365,"cost":0,"prev":"0654b0bc35284feb32213059e3f1c692847658e30bbb43c2e1524a3aaa105cf8","hash":"3dfce7c75d2bdd7f44eb7babccdd29f45de3192b25afc46943904530a7d567c9"},{"ts":"2026-07-07T04:07:22.221Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"3dfce7c75d2bdd7f44eb7babccdd29f45de3192b25afc46943904530a7d567c9","hash":"01187cddf28d56645475910ecd89181b1b9324105aaa1f82dce7d902b75b75ee"},{"ts":"2026-07-07T04:07:26.211Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"Catalogue contains one explicit herniated-disc anecdote for BPC-157 (c5): a single Reddit-style report of reduced radicular pain after 8 weeks with PT, labeled anecdotal n=1. Multiple duplicate nausea reports (c6, c122–c156) also exist as anecdotes. All other herniated-disc content in the graph is preclinical or mechanistic; no controlled human data on discs. Interaction_risk / limitations claims (c120, c67) rank first for safety questions.","tokens_in":7342,"tokens_out":203,"cost":0,"prev":"01187cddf28d56645475910ecd89181b1b9324105aaa1f82dce7d902b75b75ee","hash":"e5e91e9e60d2ac4c5b60356d332f7bf4995f2dbc1abe2ee93abd899f2a0c15e0"},{"ts":"2026-07-07T04:07:34.679Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Good experiences logged: one Reddit user (elbow tendinopathy) reported return to climbing after eight weeks with the elbow described as “almost 100 percent healed” (anecdotal). Several self-test posts describe reduced back or knee pain after eight weeks but include no imaging follow-up. One anecdotal report states BPC-157 helped calm inflammation and rebuild gut lining. One anecdotal report states positive outcome for combined BPC-157/TB-500 in systemic tissue and tendon healing. Bad experiences logged: multiple entries (c6, c122–c156) record one user who reported nausea within two weeks and discontinued use (anecdotal, n=1). No human interaction_risk or limitations-slot claims appear in the catalogue for this query.","tokens_in":7321,"tokens_out":305,"cost":0,"prev":"e5e91e9e60d2ac4c5b60356d332f7bf4995f2dbc1abe2ee93abd899f2a0c15e0","hash":"ff47ac45f51ea1b212d50e0e9686902b8cd34630d30610d878bd945e99af15ad"},{"ts":"2026-07-07T04:07:35.221Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ff47ac45f51ea1b212d50e0e9686902b8cd34630d30610d878bd945e99af15ad","hash":"7ec2c03a4ae59b71953abc726854981ef451f216e4b31dd45c0c5dfab3360798"},{"ts":"2026-07-07T04:09:28.333Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers BPC-157 (bpc-157) with one L4-L5 herniation anecdote (reduced radicular pain after 8 weeks + PT, n=1) plus general tendon/muscle healing preclinical claims; recovery-stack-herniated-disc and bpc-ara-herniated-disc slugs exist but contain no populated claims on stacks for herniated discs; TB-500 appears only in one combined anecdotal claim for systemic tissue/tendon healing (not disc-specific); ARA-290 slugs exist with no disc claims; limitations slot (c120) and long-term safety unknown (c67) must be cited first. Gaps: no human data on disc healing, no interaction_risk data, no dosing information, no stack protocols, no imaging-confirmed outcomes.","tokens_in":7351,"tokens_out":325,"cost":0,"prev":"7ec2c03a4ae59b71953abc726854981ef451f216e4b31dd45c0c5dfab3360798","hash":"c9b44249e64ddc336c5e3a6999da11c07d2592e5c63c4b3ba346acf498e5fc99"},{"ts":"2026-07-07T04:09:28.829Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"c9b44249e64ddc336c5e3a6999da11c07d2592e5c63c4b3ba346acf498e5fc99","hash":"6b299d35a199518ce3531ce4b52228c21665e8616d8df4f4ea0438def9257c64"},{"ts":"2026-07-07T04:09:35.041Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"Catalogue covers 2 explicit herniated-disc anecdotes under BPC-157 (global_id bpc-157:c5: one user with L4-L5 herniation reported reduced radicular pain after 8 weeks BPC-157 + PT; bpc-157:c6: one user reported nausea within two weeks and discontinued). Broader anecdotal tier (bpc-157:c101, c111 and others) mentions tissue/tendon healing or gut effects but does not reference discs. Multiple duplicate nausea reports (c122–c158) are low-weight repeats. No interaction_risk or limitations-slot claims are present for this condition. Recovery-stack-herniated-disc, bpc-ara-herniated-disc and ara-290-herniated-disc slugs are listed in the graph but supply no additional anecdote text in the provided topology.","tokens_in":7347,"tokens_out":312,"cost":0,"prev":"6b299d35a199518ce3531ce4b52228c21665e8616d8df4f4ea0438def9257c64","hash":"be8298cd7ad4fedf788108a1fe0b2053fa6ded5316f937e0d0a1e61195ec1d5d"},{"ts":"2026-07-07T04:09:41.677Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Good experiences logged: one user with L4-L5 herniation reported reduced radicular pain after 8 weeks with PT (anecdotal). Several Reddit self-test posts describe reduced back or knee pain after 8 weeks (no imaging). One user described elbow tendinopathy as “almost 100 percent healed” after eight weeks and return to climbing. Anecdotal reports of calmed inflammation and gut lining repair; positive anecdotal report for combined BPC-157/TB-500 in systemic tissue and tendon healing.\n\nBad experiences logged: multiple duplicate claims (c6, c122–c158) record one user who reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1).","tokens_in":7329,"tokens_out":301,"cost":0,"prev":"be8298cd7ad4fedf788108a1fe0b2053fa6ded5316f937e0d0a1e61195ec1d5d","hash":"f16873f2bd7c02b72b9e6c5a596ad3bfda1622ad05d3ee6594749285366922f0"},{"ts":"2026-07-07T04:09:42.197Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f16873f2bd7c02b72b9e6c5a596ad3bfda1622ad05d3ee6594749285366922f0","hash":"86e4ae0c1683dd31877d0285bf4c6ad0d6a414793ee3051cfce4436b7da964eb"},{"ts":"2026-07-07T04:40:36.869Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"The catalogue covers BPC-157 (slug bpc-157) and TB-500 (slug tb-500) plus recovery-stack articles (recovery-stack-herniated-disc, recovery-stack-intro, bpc-ara-herniated-disc, ara-290-herniated-disc) that mention these peptides for herniated-disc contexts. Evidence is almost entirely preclinical (rat tendon/muscle models) or anecdotal (one L4-L5 herniation report of reduced radicular pain after 8 weeks BPC-157 + PT; several nausea reports leading to discontinuation). No human RCTs for disc herniation exist in the topology. Interaction_risk / limitations claims (c120, c67) must be cited first: long-term human safety unknown, no dosing data, source monoculture problem, and the catalogue is not medical advice. Gaps: no data on stacking BPC-157 with ARA-290 or other peptides for discs; no imaging-confirmed outcomes; no interaction data with common pain meds or spine conditions.","tokens_in":7362,"tokens_out":372,"cost":0,"prev":"86e4ae0c1683dd31877d0285bf4c6ad0d6a414793ee3051cfce4436b7da964eb","hash":"93cfb0ae212bc2d345bfbc76916a09293086b0fcc2a68228e233e809b359f634"},{"ts":"2026-07-07T04:40:37.352Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"93cfb0ae212bc2d345bfbc76916a09293086b0fcc2a68228e233e809b359f634","hash":"97c942eda831c32a44503552ef5c3d6baebd3318e93a6af965f4190c80701cd2"},{"ts":"2026-07-07T04:40:41.610Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"The catalogue lists two BPC-157 herniated-disc anecdotes (global_id bpc-157:c5 and bpc-157:c6). c5 is a single Reddit-style self-report of reduced radicular pain after 8 weeks with PT (tier:anecdotal, weight 0.3). c6 is a single self-report of nausea leading to discontinuation (tier:anecdotal, weight 0.3). No other herniated-disc anecdotes appear in the listed slugs. Interaction_risk / limitations claims (bpc-157:c120, bpc-157:c67) are present and should be cited first for safety questions. All anecdotes are quote_gated:false but carry low weight; the topology contains no controlled human data on disc herniation.","tokens_in":7358,"tokens_out":290,"cost":0,"prev":"97c942eda831c32a44503552ef5c3d6baebd3318e93a6af965f4190c80701cd2","hash":"fae0c04f5d97ea701df04fe323bdb506b605d5619037f116b23d6a46f2298544"},{"ts":"2026-07-07T04:40:49.450Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Good experiences logged (anecdotal tier): one user with L4-L5 herniation reported reduced radicular pain after 8 weeks with PT (c5); one user described elbow tendinopathy returning to climbing after 8 weeks with elbow “almost 100 percent healed” (s14); several self-test posts describe reduced back or knee pain after 8 weeks (s15, s17, s18); anecdotal reports of calming inflammation and rebuilding gut lining (c101); anecdotal positive for combined BPC-157/TB-500 in systemic tissue and tendon healing (c111). Bad experiences logged (anecdotal tier): multiple duplicate entries state one user reported nausea within two weeks and discontinued (c6, c122, c124, c126, c128, c130, c132, c134, c136, c138, c140, c142, c144, c146, c148, c150, c152, c154, c156, c158, c160). Scientific evidence tier is limited to a 2-person IV pilot showing no adverse effects (c3) and reviews noting sparse human data overall (c24, c67). No interaction_risk or limitations-slot claims appear in the provided topology for safety or combinations.","tokens_in":7332,"tokens_out":393,"cost":0,"prev":"fae0c04f5d97ea701df04fe323bdb506b605d5619037f116b23d6a46f2298544","hash":"1b87febea036a3279427a2f96b1fa207f3e73eea795b75db0b4a106ded74331a"},{"ts":"2026-07-07T04:40:49.933Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1b87febea036a3279427a2f96b1fa207f3e73eea795b75db0b4a106ded74331a","hash":"26d75a539405733345dc2c3774adc01e7532bfd3c78357f150acc45b82237632"},{"ts":"2026-07-07T05:17:49.830Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers: BPC-157 (preclinical tendon/muscle/gut models + 1 anecdotal L4-L5 herniation report of reduced radicular pain after 8 weeks with PT — c5:bpc-157); BPC-157 + TB-500 anecdotal stack for systemic tissue/tendon healing (c111:bpc-157); recovery-stack-herniated-disc and bpc-ara-herniated-disc slugs exist but contain no populated claims in the provided topology. Gaps: no human trials, no imaging outcomes, no interaction_risk data, no ARA-290 or TB-500 standalone herniated-disc claims, long-term safety unknown (c67:bpc-157), and all human evidence is sparse/pilot only. No dosing or treatment information is present.","tokens_in":7370,"tokens_out":318,"cost":0,"prev":"26d75a539405733345dc2c3774adc01e7532bfd3c78357f150acc45b82237632","hash":"0fa4ca3b2f84314de13bafe191c801dc8d941545809a3d3d617f07c701744bbf"},{"ts":"2026-07-07T05:17:53.856Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0fa4ca3b2f84314de13bafe191c801dc8d941545809a3d3d617f07c701744bbf","hash":"fa5e4aaed497b2111533d9b7f2f2ad58560f1c39d57c587fc2a6dae5c5d77fc5"},{"ts":"2026-07-07T05:18:02.427Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"Catalogue lists one direct herniated-disc anecdote: c5 (global_id bpc-157:c5) — one Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 plus PT (anecdotal, n=1, tier=anecdotal, weight=0.3). Additional anecdotes exist for tendon/muscle/gut issues (e.g., c101, c111) but are not disc-specific. No interaction_risk or limitations-slot claims appear for herniated discs. Multiple duplicate nausea reports (c6, c122–c162) are catalogued as anecdotal negative outcomes.","tokens_in":7366,"tokens_out":258,"cost":0,"prev":"fa5e4aaed497b2111533d9b7f2f2ad58560f1c39d57c587fc2a6dae5c5d77fc5","hash":"20df4d8232e87f63e0f37252b43ee8dba748a05489df1c9d59a1405f4db15712"},{"ts":"2026-07-07T05:18:17.702Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"Good experiences logged for BPC-157: one Reddit user with elbow tendinopathy reported returning to climbing after 8 weeks with the elbow described as “almost 100 percent healed” (anecdotal); several self-test Reddit posts note reduced back or knee pain after 8 weeks with no imaging follow-up (anecdotal); one anecdotal claim states BPC-157 helped calm inflammation and rebuild gut lining; one anecdotal claim states positive results for combined BPC-157/TB-500 in systemic tissue and tendon healing. Bad experiences logged: multiple duplicate anecdotal entries (c6, c122–c162) report nausea within two weeks leading to discontinuation (anecdotal, n=1 each). No interaction_risk or limitations-slot claims appear in the provided topology for safety or combinations. All human evidence remains limited to one 2-person pilot showing short-term safety (c3); long-term safety unknown (c67).","tokens_in":7345,"tokens_out":374,"cost":0,"prev":"20df4d8232e87f63e0f37252b43ee8dba748a05489df1c9d59a1405f4db15712","hash":"4f5eb73dc1d32df21248fe560e36481a70908d244bb658792bbed700511fdbe5"},{"ts":"2026-07-07T05:18:21.955Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4f5eb73dc1d32df21248fe560e36481a70908d244bb658792bbed700511fdbe5","hash":"7be4e7159dc2e1700164eb6397cde699f2a43ce7b308994dff60b6959a0c28ee"},{"ts":"2026-07-07T05:22:19.469Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"what good and bad experiences are logged for BPC-157?","response":"Scientific tier: one small human pilot (s3) reported no adverse effects after up to 20 mg IV in two adults (c3). Multiple reviews note human data are limited to three small pilots with no controls (s19, s20, s27) and long-term safety is unknown (c67). All other positive findings are from rat/mouse tendon, muscle, and gut models (s1, s11, s57, s58, s25). Anecdotal tier (Reddit/X): positive reports include one user with elbow tendinopathy claiming near-full return to climbing after 8 weeks (s14), several self-reports of reduced back/knee pain after 8 weeks without imaging (s15, s17, s18), and one herniated-disc user noting less radicular pain with PT (c5). Negative report: one user experienced nausea within two weeks and stopped (c6, c122 and duplicates). Multiple duplicate nausea entries exist but remain single-source (n=1). No interaction_risk or limitations-slot claims list specific drug/condition conflicts.","tokens_in":7347,"tokens_out":349,"cost":0,"prev":"7be4e7159dc2e1700164eb6397cde699f2a43ce7b308994dff60b6959a0c28ee","hash":"e89cbd323070910a1aaec090997257b397d13e637f6fa611cbd3a9952d2f43b4"},{"ts":"2026-07-11T14:38:16.691Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what peptide stack does the catalogue cover, and what gaps remain?","response":"Catalogue covers BPC-157 (bpc-157) and TB-500 (tb-500) in the context of herniated-disc recovery. One anecdotal claim (global_id recovery-stack-herniated-disc:c5) describes a single user reporting reduced radicular pain after 8 weeks of BPC-157 plus physical therapy for L4-L5 herniation. Additional anecdotal claims note BPC-157/TB-500 combinations for systemic tissue and tendon healing (bpc-157:c111). Limitations claims state human data are sparse, long-term safety unknown, and no dosing or protocol recommendations exist (bpc-157:c120, c67). No dedicated stack articles for herniated discs appear in the topology beyond the intro and BPC/TB-500 mentions.","tokens_in":7436,"tokens_out":320,"cost":0,"prev":"e89cbd323070910a1aaec090997257b397d13e637f6fa611cbd3a9952d2f43b4","hash":"48d433c74ab8d44915d95dd8068f762e09e3f412f36eb4a5406ac5b20c5a492b"},{"ts":"2026-07-11T14:38:25.369Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"1 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"48d433c74ab8d44915d95dd8068f762e09e3f412f36eb4a5406ac5b20c5a492b","hash":"53e63f21c0e35f4232be8d936421f4f880a0ac74423d877f23071427e52b2c90"},{"ts":"2026-07-11T14:38:41.022Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH — I have herniated discs: what does the catalogue say now about anecdotes?","response":"The catalogue lists three tiers of herniated-disc anecdotes for BPC-157: (1) one Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks of BPC-157 plus physical therapy (global_id bpc-157:c5, tier=anecdotal, weight=0.3); (2) several self-test posts describe reduced back or knee pain after eight weeks but include no imaging follow-up (bpc-157 section “What people say on Reddit”); (3) duplicate nausea reports (multiple instances of the same anecdote, each labeled anecdotal n=1, weight=0.3). No other slugs in the topology contain herniated-disc anecdotes. All listed items are pre-ranked as low-weight anecdotal claims; interaction_risk / limitations claims (c120, c67) are cited first per safety-first ordering.","tokens_in":7432,"tokens_out":285,"cost":0,"prev":"53e63f21c0e35f4232be8d936421f4f880a0ac74423d877f23071427e52b2c90","hash":"46d40e539456ce63dd262d287fefcdcf80c9bfbd0bb451692e38e1da39cbc54c"},{"ts":"2026-07-11T14:39:04.266Z","model":"grok/grok-4.3","action":"ask","prompt":"","input":"SELFTEST GRAPH FN — what good and bad experiences are logged for BPC-157?","response":"From the topology: Good experiences logged for BPC-157 are all anecdotal (tier:anecdotal). One Reddit user with L4-L5 herniation reported reduced radicular pain after 8 weeks with PT (c5). Another user with elbow tendinopathy reported returning to climbing after eight weeks and described the elbow as “almost 100 percent healed” (s14). Several self-test posts describe reduced back or knee pain after eight weeks (s15, s17, s18). Additional anecdotes mention calming inflammation and rebuilding gut lining (c101) and positive effects for combined BPC-157/TB-500 in tissue and tendon healing (c111). Bad experiences: multiple duplicate claims (c6, c122–c164) state one user reported nausea within two weeks and discontinued BPC-157 (anecdotal, n=1). All human safety data are limited to a two-person pilot showing no short-term adverse effects (c3); long-term safety and side effects are unknown (c67). No interaction_risk claims are present. Marketing volume is separated from evidence per ranking rules.","tokens_in":7413,"tokens_out":346,"cost":0,"prev":"46d40e539456ce63dd262d287fefcdcf80c9bfbd0bb451692e38e1da39cbc54c","hash":"68acdaa4e0f1607cec97e27e4e77ccf74e875d243ad2958b223c50a2e6148408"},{"ts":"2026-07-11T14:39:12.691Z","model":"ingest:deterministic","action":"sources","prompt":"","input":"bpc-157","response":"0 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"68acdaa4e0f1607cec97e27e4e77ccf74e875d243ad2958b223c50a2e6148408","hash":"88b67b054fe9bc082e3cc6c0557ff87638e4197e9161fdba4675b2817e5d5d5c"},{"ts":"2026-07-17T02:38:30.623Z","model":"owner","action":"voxel_divide","prompt":"","input":"bpc-157","response":"25 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"88b67b054fe9bc082e3cc6c0557ff87638e4197e9161fdba4675b2817e5d5d5c","hash":"de787dea24c6ff3ebaa8d9db3eebb02bbabff6153d0cefba7bd038e79cdbedba"},{"ts":"2026-07-22T20:12:01.648Z","model":"user","action":"claim","prompt":"","input":"bpc-157 c167","response":"Regulatory status as of July 2026 (verify against FDA docket FDA-2025-N-6895): BPC-157 is NOT FDA-approved for human use. It was placed in 503A Category 2 (significant safety concerns) in late 2023, effectively barring compounding, then removed from Category 2 on 22 April 2026 after nomination withdrawal — but was NOT moved to Category 1, leaving it in a regulatory gray zone, neither prohibited nor authorized. A Pharmacy Compounding Advisory Committee review was scheduled for 23 July 2026. It has no USP/NF monograph. Sold as research-use-only; that legality covers the sale, not human use. Sources: FDA 503A bulk substances list; opss.org; newdrugloft.com regulatory update 2026-05. Claimed by Claude Fable 5 under cap_e3772257eb713407.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"de787dea24c6ff3ebaa8d9db3eebb02bbabff6153d0cefba7bd038e79cdbedba","hash":"0716e3b20a97fa04563a900b6833ea444ef85ee01b60895616ee0a7471855e88"},{"ts":"2026-07-22T20:12:04.340Z","model":"user","action":"claim","prompt":"","input":"bpc-157 c168","response":"Anti-doping and military status: BPC-157 is on the World Anti-Doping Agency Prohibited List class S0 (non-approved substances), so it is banned in competitive sport at all times. It also appears on the US DoD Prohibited Dietary Supplement Ingredients List (DoDI 6130.06), prohibited for Service Members. Athletes and military personnel face specific sanctions distinct from the general regulatory gray zone. Source: WADA Prohibited List; usada.org. Claimed by Claude Fable 5 under cap_e3772257eb713407.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"0716e3b20a97fa04563a900b6833ea444ef85ee01b60895616ee0a7471855e88","hash":"10774e844a8162e603a29c0df2a0da53d46ae99da423a941da68e1cb161e0181"}]}